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Humanmesenchymal stem cells (hMSCs) are primary cells with
high clinical relevance that could be enhanced through genetic
modification. However, gene delivery, particularly through
nonviral routes, is inefficient. To address the shortcomings of
nonviral gene delivery to hMSCs, our lab has previously
demonstrated that pharmacological “priming” of hMSCs
with clinically approved drugs can increase transfection in
hMSCs by modulating transfection-induced cytotoxicity. How-
ever, even with priming, hMSC transfection remains inefficient
for clinical applications. This work takes a complementary
approach to addressing the challenges of transfecting hMSCs
by systematically investigating key transfection parameters
for their effect on transgene expression. Specifically, we inves-
tigated two promoters (cytomegalovirus [CMV] and elonga-
tion factor 1 alpha), four DNA vectors (plasmid, plasmid
with no F1 origin, minicircle, and mini-intronic plasmid),
two cationic carriers (Lipofectamine 3000 and Turbofect),
and four donors of hMSCs from two tissues (adipose and
bone marrow) for efficient hMSC transfection. Following sys-
tematic comparison of each variable, we identified adipose-
derived hMSCs transfected with mini-intronic plasmids con-
taining the CMV promoter delivered using Lipofectamine
3000 as the parameters that produced the highest transfection
levels. The data presented in this work can guide the develop-
ment of other hMSC transfection systems with the goal of pro-
ducing clinically relevant, genetically modified hMSCs.
INTRODUCTION
Human mesenchymal stem cells (hMSCs) are under extensive
research for applications in cell and gene therapeutics1,2 due to their
ease of isolation frommultiple adult tissues,3 their multipotent differ-
entiation potential,4 and their ability to home to sites of injury and
reduce inflammation upon transplantation.5,6 These therapeutic
properties could be enhanced or expanded through genetic modifica-
tion accomplished via delivery of exogenous genes, e.g., delivery of a
DNA vector encoding for differentiation factors to enhance hMSC
tissue engineering applications.7 Genetic modification of hMSCs
can be accomplished via viral or nonviral methods.8,9 While viral
transduction is efficient, it suffers from safety issues related to immu-
nogenicity and insertional mutagenesis.9,10 Nonviral gene delivery,
which typically consists of condensing an anionic DNA vector with
a cationic carrier to form nano-sized complexes that are capable of
in vitro transfection,11 overcomes many challenges associated with
viral methods; however, nonviral gene delivery suffers from ineffi-
ciency, especially in hMSCs.12
To address the shortcomings of nonviral gene delivery to hMSCs, our
group has demonstrated that pharmacological “priming” of cells prior
to or simultaneously with application of nonviral DNA complexes
can improve transfection in hMSCs.13–16 Specifically, we have shown
that the glucocorticoid, dexamethasone, can significantly increase
transfection efficiency and transgene expression in multiple donors
of hMSCs from different tissues, relative to a vehicle control
(VC),13 by modulating transfection-induced stress pathways and
apoptosis.14,15 Additionally, we have expanded our hMSC transfec-
tion priming library by screening a collection of 707 FDA approved
drugs for drug repurposing17 and identified new candidate priming
agents that can significantly improve transfection compared to a
VC.16 However, even with priming, nonviral gene delivery to hMSCs
remains inefficient for clinical applications.
In addition to priming strategies to improve transfection in hMSCs,
research has shown that many factors can contribute to the success
of nonviral gene delivery systems, such as the promoter sequence,18
DNA vector,19–22 bacterial elements,19 cationic carrier,23 hMSC
donor,24 and hMSC tissue source.13–15 Two common promoters,
the viral cytomegalovirus (CMV) promoter and the endogenous elon-
gation factor 1 alpha (EF1a) promoter, have shown varying degrees of
transfection outcomes in hMSCs.14,25 For example, we have shown
increased transfection in hMSCs with a DNA vector containing the
viral CMV promoter compared to a DNA vector containing the
EF1a promoter,14 while others have shown the opposite in hMSCs
when using those promoters in different DNA vectors.25 In addition
to promoters, the DNA vectors themselves, and in particular the
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bacterial elements contained within the DNA vectors (e.g., bacterial
origins of replication, like the F1 origin,26 and antibiotic resistance
genes) can modulate transfection. For example, minicircle vectors
(MCs), which do not contain any bacterial elements, have shown
increased transfection efficiency in hMSCs compared to conventional
plasmids7 that contain bacterial elements. Alternatively, mini-in-
tronic plasmids (MIPs), which include bacterial elements within an
engineered intron, have shown enhanced transfection in vitro and
in vivo compared to conventional plasmids, possibly due to the inclu-
sion of an intron.19,22 However, MIPs have not been investigated in
the context of hMSC transfection. In addition to vector elements,
different cationic carriers, such as polymers or lipids, have shown
varying degrees of transfection in hMSCs.23 Beyond DNA vector
and cationic carrier, hMSC donor and tissue source (i.e., adipose or
bone marrow) can affect transfection success as well.13–15,24
However, even with the above studies, these variables and their effects
on nonviral gene delivery to hMSCs have yet to be systematically exam-
ined, and thus the objective of this work was to investigate four DNA
vectors (plasmid DNA, plasmid DNA with no F1 origin of replication,
MIPs, andMCs) and twopromoters (CMVandEF1a), complexedwith
two commercially available cationic carriers (Lipofectamine 3000 and
Turbofect) for their effects on transfection in hMSCs from four donors
derived from two tissue sources (adipose- and bone-marrow-derived).
This work systematically studies the key aspects of nonviral gene deliv-
ery systems as they pertain to hMSCs and offers insight into design pa-
rameters that can be exploited and further explored to develop efficient
gene delivery systems for cells of high clinical significance.
RESULTS
The objective of this study was to investigate the effects of different
promoters, DNA vectors, and cationic carriers on transfection in
hMSCs from different donors and tissues. Specifically, we investigated
two promoters (CMV and EF1a; Table 1) and four DNA vectors
(plasmid, plasmid with no F1 origin of replication, MC, and MIP; Ta-
ble 1; Figure 1), delivered using two commercially available cationic
carriers (Turbofect [polymer-mediated] and Lipofectamine 3000
[lipid-mediated]) to cells from four hMSC donors (D1, D2, D3, and
D4; Table S1) derived from two tissue sources (bone-marrow-derived
and adipose-derived; Table S1) in order to identify transfection pa-
rameters that significantly (p < 0.05) affect transfection efficiency
and transgene production in hMSCs. The effects on transfection effi-
ciency were assayed by fluorescence imaging of an expressed trans-
genic fusion protein of enhanced green fluorescent protein (EGFP)
with luciferase, normalized by total cell count (Hoechst 33342, nuclei
stain), to obtain transfection efficiencies for all conditions. Imaging
results were then verified by a chemical assay for transgenic luciferase
activity, in relative light units (RLUs), normalized by total cellular
protein values (RLU/mg Protein). It is important to note that due
to the varying sizes of DNA vectors and promoters tested, both
mass of DNA delivered and DNA copy number (i.e., molarity of
transgene) were normalized for each promoter and cationic carrier
in order to properly compare conditions (Table 2).
Given all of the variables above, this study tested 64 conditions, in trip-
licate on duplicate days (n = 6), to identify key transfection parameters
(Tables 1; Table S1) that modulate hMSC transfection efficiency (Fig-
ures 2A and 2C) and transgene production (Figures 2B and 2D). Both
outcomes varied widely as a function of each parameter, e.g., D3
bone-marrow-derived hMSCs (hBMSCs) transfected with the conven-
tional CMV plasmid complexed with Turbofect produced transfection
efficiencies around 35%, the highest of our study (Figure 2A), while D2
adipose-derived hMSCs (hAMSCs) transfected with CMV MIP com-
plexed with Lipofectamine 3000 produced the highest transgenic lucif-
erase activity of our study (Figure 2D). When comparing fold change
differences between all possible comparisons (Figures S1 and S2), D1
hAMSCs transfected with EF1a MIP vectors complexed with Lipofect-
amine 3000 increased transfection efficiency almost 2-fold and trans-
genic luciferase activity by more than 6-fold compared to D1 hAMSCs
transfected with the conventional CMV plasmid complexed with Lipo-
fectamine 3000 (Figures S1A andS2A, respectively).However, given the
multitude of parameters and combinations studied, data analysis was
performed to assess whether there were any significant interactions be-
tween variables. Analyzing the transfection data as a negative binomial
identified all two-way interactions as significant (Table S3), therefore,
further analysis of the effects of each individual parameter on transfec-
tion outcomes was conducted, as described next.
Promoter selection can affect transfection in hMSCs
In order to understand promoter effects on hMSC transfection, trans-
gene expression data (i.e., number EGFP-positive cells and total cells
counts) were grouped by promoter (CMV or EF1a) for all hMSCs
(D1, D2, D3, and D4), cationic carriers (Turbofect and Lipofectamine
3000), and DNA vectors (plasmid, no F1, MC, andMIP) and depicted
as scatterplots of total cell counts versus number of EGFP-positive
cells (Figure 3). These plots were sectioned into four quadrants for
each promoter as described in the methods and legend for Figure 3.
Analyzing transfection data as a function of promoter revealed differ-
ences between the CMV and EF1a promoters, as the CMV promoter
resulted in eight conditions (transfection efficiencies for conditions in
which hAMSCs were transfected with MIPs; Figure 3A) out of 192 to-
tal conditions/replicates in quadrant 2 (Q2; i.e., high transgene
expression and low total cell counts), whereas the EF1a promoter
Table 1. DNA vector information




CMV pUC origin of replication
EF1a
EF1a F1 origin of replication
Kanamycin resistance marker
CMV No F1 CMV pUC origin of replication




MIP CMV CMV pUC origin of replication
MIP EF1a EF1a RNA-OUT selectable marker
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resulted in no conditions in Q2 (Figure 3B). Furthermore, both pro-
moters resulted in a majority of the transfection conditions within Q3
(i.e., low transgene expression and low total cell counts). Analyzing
EGFP-positive cell counts as a negative binomial variable, with total
cell counts as an offset term, showed that in terms of promoter effects,
the CMV promoter resulted in significantly higher EGFP-positive cell
counts than the EF1a promoter at the same total cell count within vec-
tor (p < 0.0001, Table S4), cationic carrier (p < 0.0001, Table S5), and
donor (p < 0.0001, Table S6).
DNA vector bacterial elements affect transfection in hMSCs
In a similar manner used to compare promoters, transgene expression
data (i.e., number of EGFP-positive cells and total cell counts) were
grouped by the bacterial elements contained within each DNA vector
(Table 1; Figure 4). Transgene expression data for the 16 conventional
plasmid conditions, which contain the most bacterial elements (Table
1), were analyzed (i.e., CMV and EF1a; Table 1; Figure 2). Conditions
in which hMSCs were transfected with conventional plasmids gener-
ally had transgene expression data in Q3 (i.e., low transgene expres-
sion and low total cell counts; Figure 4A). Removal of the F1 origin
of replication from the conventional plasmid (No F1) resulted in
more transfection conditions with higher EGFP-positive cell counts
(i.e., Q1, more transgene expression) or higher total cell counts (i.e.,
Q4; Figure 4B) compared to conventional plasmids; however, condi-
tions in which hMSCs were transfected with No F1 vectors generally
had transgene expression data within Q3 (Figure 4B). Transgene
expression data for the 16 MC conditions were also analyzed (Table
1; Figure 2). Conditions in which hMSCs were transfected with
MCs generally produced transgene expression data that were within
Q3 (i.e., low transgene expression and low total cell counts; Fig-
ure 4C). Conditions where hMSCs were transfected with MCs also
produced a lower number of EGFP-positive cells (Figure 4C)
compared to conditions where hMSCs were transfected with either
conventional plasmids or No F1 vectors (Figures 4A and 4B, respec-
tively). Finally, the transgene expression data for the 16 MIP condi-
tions (Table 1; Figure 2) were analyzed. Conditions in which hMSCs
were transfected with MIPs generally produced transgene expression
data that were within Q3 (i.e., low transgene expression and low total
cell counts; Figure 4D); however, conditions where hMSCs were
transfected with MIPs produced more transgene expression data
that were within Q2 (i.e., high transgene expression and high total
cell counts; Figure 4D) compared to conditions where hMSCs were
transfected with conventional plasmids (Figure 4A), No F1 vectors
(Figure 4B), and MCs (Figure 4C). Analyzing EGFP-positive cell
counts as a negative binomial variable with total cell counts as an
offset term, indicated significant differences in EGFP-positive cell
counts between vectors at the same total cell count within promoter
(p < 0.01, Table S7), cationic carrier (p < 0.0001, Table S8), and donor
(p < 0.05, Table S9). Furthermore, MIP vectors resulted in signifi-
cantly higher EGFP-positive cell counts compared to all other vectors
tested in hMSCs (p < 0.001, Table S9), except for D4 hMSCs trans-
fected with plasmids (p < 0.07, Figure 4; Table S9).
Cationic carrier can affect hMSC transfection
In a similar manner used to compare promoters and bacterial ele-
ments, transgene expression data (i.e., number of EGFP-positive cells
Figure 1. Representative schematics of DNA vectors investigated in this study
DNA vector diagrams are not to scale. DNA vector diagramswere created with SnapGene. F1 Ori, F1 origin of replication; poly(A), polyadenylation signal; MC, minicircle; MIP,
mini-intronic plasmid.
www.moleculartherapy.org
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and total cell counts) were grouped for the two commercially available
cationic carriers (Figure 5). Conditions that made use of Turbofect, a
polymer-based cationic carrier, generally had transgene expression
data within Q3 (i.e., low transgene expression and low total cell
counts; Figure 5A), however, seven transfection conditions (condi-
tions in which hAMSCs were transfected with MIP CMV vectors)
of the 192 conditions/replicates were contained within Q2 (i.e.,
high transgene expression and high total cell counts; Figure 5A). Con-
ditions that made use of Lipofectamine 3000, a lipid-based cationic
carrier, had one condition within Q2 (D1 hAMSC transfected with
MIP CMV vectors; Figure 5B) but similar to Turbofect, the 64 condi-
tions that made use of Lipofectamine 3000 (Figure 2) generally pro-
duced transgene expression data within Q3 (Figure 5B). Furthermore,
analyzing EGFP-positive cell counts as a negative binomial variable,
with total cell counts as an offset term, indicated a significant differ-
ence in EGFP-positive cell counts between Lipofectamine 3000 and
Turbofect at the same total cell count within promoter (p < 0.05, Ta-
ble S10), vector (p < 0.01, Table S11), and donor (p < 0.01, Table S12);
however, due to our experimental design, it is difficult to conclude
with any statistical confidence that Lipofectamine 3000 results in
more EGFP-positive cells than Turbofect specifically between donors.
hMSC donor and tissue source can affect transfection
In a similar manner used to analyze promoters, bacterial elements,
and cationic carriers, transgene expression data (i.e., number of
EGFP-positive cell counts and total cell counts) for each hMSC donor
and tissue source were grouped (Table S1; Figure 6). Transfection of
hAMSCs generally resulted in transgene expression data within Q3
and Q4 (i.e., low transgene expression and varying total cell counts;
Figure 6A) while transfection of hBMSCs resulted in all but one con-
dition within Q3 (D4 hBMSCs transfected with No F1 CMV vector;
Figure 6B). We further separated the transgene expression data by
hMSC donor within each scatterplot in order to investigate transfec-
tion as a function of donor variability. For the two donors of hAMSCs,
D1 (orange symbols) had transfection conditions with fewer EGFP-
positive cells but higher total cell counts when compared to transfec-
tion conditions for D2 (Figure 6A; yellow symbols). However, there
was little difference in transgene expression data between the two do-
nors of hBMSCs (Figure 6B). Analyzing EGFP-positive cell counts as
a negative binomial variable, with total cell counts as an offset term,
indicated a significant difference in EGFP-positive cell counts be-
tween donors within promoter (p < 0.05, Table S13), vector (p <
0.05, Table S14), and cationic carrier (p < 0.05, Table S15); however,
due to our experimental design in which we blocked by donor, further
interpretation of statistical analysis on donor effects is not
appropriate.
DISCUSSION
hMSCs are primary cells isolated from a variety of tissue with high
clinical relevance,1,2 which could be enhanced through genetic modi-
fication. However, gene delivery, particularly through nonviral routes,
is inefficient.8,12–16,24We have previously reported enhanced nonviral
gene delivery to hMSCs by priming with pharmacologic agents,16 spe-
cifically with the glucocorticoid dexamethasone;13–15 however, work
remains to improve nonviral gene delivery to hMSCs, in particular
through evaluation of key variables of the nonviral gene delivery sys-
tem. This work systematically compares the key variables of nonviral
gene delivery systems (e.g., DNA vector type, DNA vector bacterial
elements, promoter, cationic carrier, and donor and tissue source)
and the effects of these variables on transfection outcomes. The trans-
fection outcomes varied widely for all 64 conditions tested (Tables 1;
Table S1; Figure 2), therefore, deliberate grouping of variables was
conducted in order to study the effects of each variable on hMSC
transfection.
In order to investigate the effects of DNA vector modification on
hMSC transfection, we first aggregated imaging transfection data
(i.e., number of EGFP-positive cells and total cell counts) for all con-
ditions tested and analyzed a single variable at a time. The first vari-
able that we investigated was promoter used to drive expression of the
transgene. The two promoters tested in this work (i.e., CMV and
EF1a) are widely used promoters for gene delivery shown to produce
high levels of transfection in numerous cell types.25,27 Even so, the
CMV promoter has shown significantly increased transfection levels
compared to the EF1a promoter, especially in hMSCs.14 Consistent
with other published work, in this work, the CMVpromoter did result
in significantly increased EGFP-positive cell counts compared to the
EF1a promoter when only the effects of the promoter were analyzed
(Figure 3; Table S4–S6). This significant increase in transfection by
the CMV promoter compared to the EF1a promoter may be from
increased transcription of the transgene, as Antonova and colleagues
have shown that the CMV promoter produces more transgenic
mRNA transcripts compared to other promoters in mouse and pri-
mary human fibroblasts.28 However, in this current report there
was no significant increase in transgenic mRNA transcripts in
hAMSCs from the CMV promoter compared to the EF1a promoter
for any of the conditions tested at either 12 or 24 h after delivery of
the transgene (Figure S3). While not significant, we did observe slight
increases in transgenic mRNA transcripts in hAMSCs transfected
with CMV DNA vectors compared to hAMSCs transfected with the
same DNA vector with the EF1a promoter. However, these increases
in transgenic mRNA transcripts likely do not contribute to the








vector for 1 mg/mL stocks
CMV 6.3 1 0
EF1a 6.9 1 0
CMV No F1 5.9 0.94 0.06
EF1a No F1 6.5 0.94 0.06
MC CMV 3.3 0.52 0.48
MC EF1a 3.9 0.57 0.43
MIP CMV 4.7 0.75 0.25
MIP EF1a 5.4 0.78 0.22
Kbp, kilobase pairs
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significant increases in transfection efficiency and transgenic lucif-
erase activity that we observed, and others have reported,14 from
the CMV promoter compared to the EF1a promoter. While this cur-
rent study confirms that the CMV promoter produces more transfec-
tion than the EF1a promoter in hMSCs frommultiple donors and tis-
sue sources, the mechanism of enhancement for the CMV promoter
needs further investigation.
Next, we investigated the effects of bacterial elements contained
within the DNA vector for their effect on transfection outcomes in
hMSCs. Conventional plasmids contain bacterial origins of replica-
tion and typically an antibiotic resistance gene for selection of
plasmid-harboring bacteria during plasmid propagation. These bac-
terial components, while necessary for DNA vector production,
have often been associated with an innate immune response through
recognition of pathogen associated molecular patterns (PAMPs;
e.g., unmethylated cytosine-phosphate-guanine [CpG]) by pattern
recognition receptors (PPRs),29,30 which may lead to transgene
silencing.31,32 Therefore, research into the development of highly effi-
cient nonviral gene delivery systems has focused on removing bacte-
rial elements from nonviral vectors.8,29 While the experiments in this
present work were not designed to study transgene silencing (i.e.,
transfection was assayed at a single time point following addition of
DNA vectors), we did observe slight increases in transgenic luciferase
activity when the F1 origin of replication (i.e., bacterial element) was
removed from conventional plasmids, compared to conventional
plasmids (Figures 2B and 2D). The F1 origin of replication is used
in conventional plasmids to replicate and package single-stranded
DNA into phages;33 however, the F1 origin of replication is not neces-
sary for conventional plasmid production or expression in mamma-
lian cells. Furthermore, Johnson and colleagues26 observed significant
increases in bactofection (i.e., delivery of genetic cargo to mammalian
cells using bacteria) of human breast cancer cells when the bacteria
were harboring plasmids with no F1 origin of replication, presumably
by rescuing DNA-induced stress. Therefore, removal of nonessential
bacterial elements within DNA vectors may increase transfection in
various cell types, particularly in hMSCs.
While removal of all bacterial elements is improbable for conven-
tional plasmid production, Chen and colleagues34 developed a
DNA vector devoid of all bacterial elements, termed MCs, and
showed increased transgene expression in vivo compared to conven-
tional plasmids. MCs are devoid of all bacterial elements, while also
having the ability to be propagated in engineered bacteria, through
excision and recombination of the expression cassette from a parental
plasmid, leaving a DNA vector that contains a promoter, transgene,
and a terminator sequence.34 MCs have since been shown to enhance
transfection in hMSCs,7,25,35–37 as well as stem cells from other spe-
cies,38,39 compared to conventional plasmids; however, in this current
study, MCs produced the lowest transfection efficiencies and trans-
gene expression observed, regardless of cationic carrier, promoter,
donor, or hMSC tissue source (Figures 2, 3, 4, 5, and 6). The large
Figure 2. Transfection efficiency and production of transgene for all 64 conditions tested
(A) Violin plots of transfection efficiency for the 32 transfection conditions where Turbofect was used as the cationic carrier. (B) Violin plots of transgenic luciferase activity
normalized to total protein amounts for the 32 transfection conditions where Turbofect was used as the cationic carrier. (C) Violin plots of transfection efficiency for the 32
transfection conditions where Lipofectamine 3000 was used as the cationic carrier. (D) Violin plots of transgenic luciferase activity normalized to total protein amounts for the
32 conditions that Lipofectamine 3000 was used as the cationic carrier. Parameters are identified within the legend provided.
www.moleculartherapy.org
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discrepancy in transfection outcomes fromMCs observed in this cur-
rent study compared to other published studies may be from our
normalization of both moles of expression cassette (i.e., transgene)
and mass of DNA delivered (Table 2). For example, Mun and col-
leagues25 observed higher transfection efficiencies in hAMSCs and
hBMSCs using an EGFP expressing MC compared to an EGFP ex-
pressing plasmid when equal moles of expression cassette were deliv-
ered (i.e., higher mass of plasmid delivered than mass of MC). Alter-
natively, Boura and colleagues36 delivered equal mass of MCs (i.e.,
higher molarity of expression cassette for MCs compared to plasmid)
encoding for human leukocyte antigen-G1 (HLA-G1) to hBMSCs as
plasmids carrying HLA-G1 and observed significantly higher expres-
sion of HLA-G1 from MCs in hBMSCs compared to a plasmid with
the same promoter. Furthermore, Zimmermann and colleagues7
showed significantly more alkaline phosphatase (ALP) activity in
hBMSCs transfected with a bone morphogenetic protein 2 (BMP2)
encoding MC compared to a conventional plasmid encoding
BMP2, when equal mass of DNA was delivered (i.e., higher molarity
of expression cassette for MCs compared to plasmid); however, when
equal moles of expression cassette was delivered (i.e., higher mass of
plasmid delivered thanmass ofMCs), BMP2 encodingMCs produced
the same levels of ALP activity compared to BMP2 encoding plas-
mids. Indeed, we have observed increased transfection in hMSCs
with MCs compared to conventional plasmids when equal mass of
DNA vector was delivered but not equal moles of expression cassette
(T.K., unpublished data); however, delivering equal mass of vectors
with drastically different sizes is not a fair comparison as there will
always be higher concentrations of expression cassette for the smaller
vector (i.e., MC) than the larger vector (i.e., conventional plasmid),
potentially increasing the probability of successful transfection for
the smaller vector. Furthermore, delivering equal moles of expression
cassette is also not a fair comparison for DNA vectors with drastically
different sizes as the larger vector (i.e., conventional plasmid) will al-
ways have more mass of DNA than the smaller vector (i.e., MC),
potentially leading to more toxicity than the smaller vector, as Zim-
mermann and colleagues observed a significant decrease in viability
for conventional plasmids compared to MCs when equal moles of
transgene were delivered (i.e., higher mass of conventional plasmid).7
Therefore, we recommend that both moles of transgene and mass of
DNA delivered need to be normalized in order to robustly compare
DNA vectors with drastically different sizes. However, whether the
transfection by MC observed in other studies is due to the lack of bac-
terial elements or the vectors’ small size compared to conventional
plasmids, or whether the lack of transfection observed in this work
is due to lower copy numbers of the expression cassette for a given
mass of DNA delivered, needs further investigation.
Another DNA vector with reduced bacterial components, which re-
tains the ability to propagate in conventional bacteria, was developed
by the Kay Lab.19 These vectors, termedMIPs, contain all bacterial el-
ements necessary for vector propagation in an engineered intron
within the expression cassette.19 The idea to incorporate bacterial el-
ements within an engineered intron in the expression cassette
stemmed from observations of in vivo transgene silencing when the
extragenic space between the 50 and 30 ends of the expression cassette
was greater than 1 kb.31 The authors hypothesized that shortening the
extragenic space between the 50 and 30 ends of the expression cassette
could allow for more efficient gene looping, a mechanism in which the
promoter and terminator regions are juxtaposed in a transcription-
dependent manner,40 thereby promoting efficient transcriptional
elongation and recycling of RNA polymerase II from the terminator
to the promoter. Their hypothesis that shortening the extragenic
Figure 3. Transgene expression data as a function of
DNA vector promoter in human mesenchymal stem
cells (hMSCs)
(A) Scatterplot showing aggregated EGFP-positive cells
and total cell counts for all transfection conditions (TableS1;
Table 1) with the CMV promoter in all donors of hMSCs. (B)
Scatterplot showing aggregated EGFP-positive cells and
total cell counts for all transfection conditions (Table S1;
Table 1) with the EF1a promoter in all donors of hMSCs.
Quadrant 1 (Q1) represents high transgene expression but
low total cell counts, which could be attributed to either
transfection-induced toxicity and/or a reduction in prolif-
eration. Q2 represents high transgene expressionwith high
total cell counts, which could be attributed to eitherminimal
transfection-induced toxicity and/or minimal reduction in
proliferation. Q3 represents both low transgene expression
and low total cell counts. Lastly, Q4 represents low trans-
gene expression but high total cell counts. It should be
noted that these quadrants were partitioned using the
highest number of EGFP-positive cells and total cell counts
that were observed in this current study; therefore, these
quadrant boundaries should not be used to evaluate con-
ditions and data from other studies. Lines represent
the Poisson regression line that best fits the data. Param-
eters are identified within the legend provided.
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space would allow for more efficient gene looping was never verified,
but Lu and colleagues19 did observe enhanced transfection with MIPs
in mice and in human cells compared to plasmids and MCs. Indeed,
MIPs produced the highest transfection efficiencies and transgene
expression in this current study in both donors of hAMSCs compared
to all other vectors, regardless of cationic carrier or promoter (Figures
2, 3, 4, 5, and 6). Additionally, we observed significantly more trans-
genic mRNA transcripts from hAMSCs transfected with MIP EF1a
compared to hAMSCs transfected with either CMV or EF1a plasmids
at 24 h (Figure S3); however, similar results were not observed for
hAMSCs transfected with MIP CMV (Figure S3). The high transfec-
tion levels from MIPs observed in this current study, as well as other
published work,19,22,41 may be from the inclusion of an intron within
the expression cassette, as others have shown increased transgene
expression42 or mRNA transcripts43 when introns were inserted
into the expression cassette. Introns have long been thought of as su-
perfluous genetic material and were traditionally removed from
transgenes prior to ligating into a DNA vector; however, introns
have been shown to play vital roles in transgene expression, such as
transcription,43 polyadenylation,44 and mRNA export and decay,45
as well as translational efficiency.46 Given the transfection levels
observed in this current study by MIPs, as well as the transgenic
mRNA transcript levels at 12 and 24 h after transfection, it is plausible
that the engineered intron within the expression cassette of MIPs
might be promoting transcription42,43 or limiting mRNA decay
(i.e., significantly higher transgenic mRNA transcripts for MIPs in
Figure 4. Transgene expression data as a function of DNA vector bacterial elements in hMSCs
(A) Scatterplot showing aggregated EGFP-positive cells and total cell counts for all plasmid vector conditions in all donors of hMSCs. (B) Scatterplot showing aggregated
EGFP-positive cells and total cell counts for all plasmid conditions with the F1 origin of replication removed (No F1) in all donors of hMSCs. (C) Scatterplot showing aggregated
EGFP-positive cells and total cell counts for all MC vector conditions in all donors of hMSCs. (D) Scatterplot showing aggregated EGFP-positive cells and total cell counts for
all MIP conditions in all donors of hMSCs. Q1 represents high transgene expression but low total cell counts, which could be attributed to either transfection-induced toxicity
and/or a reduction in proliferation. Q2 represents high transgene expression with high total cell counts, which could be attributed to either minimal transfection-induced
toxicity and/or minimal reduction in proliferation. Q3 represents both low transgene expression and low total cell counts. Lastly, Q4 represents low transgene expression but
high total cell counts. It should be noted that these quadrants were partitioned using the highest number of EGFP-positive cells and total cell counts that were observed in this
current study, therefore, these quadrant boundaries should not be used to evaluate conditions and data from other studies. Lines represent the Poisson regression line that
best fits the data. Parameters are identified within the legend provided.
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D1 hAMSCs compared to both the CMV and EF1a conventional
plasmid, regardless of promoter used; Figures S3B and S3D) or are
enhancing translation in hAMSCs42 (i.e., higher transfection effi-
ciency and transgene expression by MIPs compared to other vectors
tested regardless of promoter or cationic carrier in hAMSCs; Figure 4).
However, in hBMSCs, increases in transfection efficiency and trans-
gene expression byMIPs were only observed when the EF1a promoter
was used (Figure 2), possibly due to the incorporation of a second
intron within the EF1a promoter42 or differences in intron processing
by the cells.47 However, studies comparing transcription and transla-
tion efficiency differences from either gene looping or incorporation
of one or more introns are needed to fully elucidate the transfection
enhancements observed by MIPs in hMSCs.
In addition to the above transfection parameters, research has shown
that polymer- and lipid-mediated nonviral gene delivery efficacy can
be dependent on cationic carrier formulation; however, limited
research has been conducted on how polymer- and lipid-mediated
transfection can be affected by different DNA vectors,48 in particular
within the context of hMSCs frommultiple donors and tissue sources.
Here, two commercially available transfection reagents were used,
which represent both lipid- and polymer-based systems: Lipofect-
amine 3000 and Turbofect, respectively. These commercially avail-
able transfection reagents were chosen as they are readily available,
widely used, and have shown moderate levels of transfection in
hMSCs14–16,24 (T.K., A.H., and L.S., unpublished data). This study
did not include other modes of delivery (e.g., electroporation) given
the complexities involved in comparing carrier-based systems to
physical methods, but future studies should investigate other delivery
strategies in the context of the parameters investigated here.
In this current study, there were differences in transfection effi-
ciencies and transgene production between the two cationic carriers
(Figure 2) and Poisson regressions of aggregated transgene expression
data for each cationic carrier showed slight differences in overall
transfection trends (Figure 5). Indeed, others have shown differences
in transfection outcomes in hMSCs between polymer- and lipid-
based systems, with either polymer-49 or lipid-based23 systems pro-
ducing the highest transgene expression. Furthermore, we observed
significantly different total cell ratios for tested cationic carriers (Tur-
bofect total cell count divided by the total cell count for the same con-
dition complexed with Lipofectamine 3000, which is an indirect mea-
sure of toxicity and/or proliferative effects of Turbofect relative to
Lipofectamine 3000) between hAMSCs and hBMSCs (Figure S4),
highlighting another transfection parameter that needs to be carefully
considered in a hMSC nonviral gene delivery system. Indeed, our pre-
vious studies on hMSC transfection with lipid-based cationic carriers
extensively characterized both cellular proliferation (through meta-
bolic studies)13 and transfection-induced toxicity,15 and showed
that rescuing transfection-induced metabolic shut down and toxicity
could enhance transfection efficiency and transgene production.13,15.
Taken together, cationic carrier selection does not have a large effect
on overall transfection outcomes; however, transfection and total cell
counts, which are an indirect measure of cytotoxicity and/or prolifer-
ative nature, can be optimized if the cationic carrier is selected based
on hMSC tissue source.
Finally, hMSCs can be harvested frommultiple tissues in the adult hu-
man body50,51 and, due to their immunomodulatory effects,5,52 have
the potential for allogenic use,53 making both donor and tissue source
pertinent variables in this study. hMSCs have been shown to have
Figure 5. Transgene expression data as a function of
cationic carrier in hMSCs
(A) Scatterplot showing aggregated EGFP-positive cells
and total cell counts for all transfection conditions where
the polymer transfection reagent Turbofect was used as
the cationic carrier in all donors of hMSCs. (B) Scatterplot
showing aggregated EGFP-positive cells and total cell
counts for all vectors where the lipid transfection reagent
Lipofectamine 3000 was used as the cationic carrier in all
donors of hMSCs. Q1 represents high transgene expres-
sion but low total cell counts, which could be attributed to
either transfection-induced toxicity and/or a reduction in
proliferation. Q2 represents high transgene expression
with high total cell counts, which could be attributed to
eitherminimal transfection-induced toxicity and/orminimal
reduction in proliferation. Q3 represents both low trans-
gene expression and low total cell counts. Lastly, Q4 rep-
resents low transgeneexpressionbut high total cell counts.
It should be noted that these quadrants were partitioned
using the highest number of EGFP-positive cells and total
cell counts that were observed in this current study,
therefore, these quadrant boundaries should not be used
to evaluate conditions and data from other studies. Lines
represent thePoisson regression line that best fits the data.
Parameters are identified within the legend provided.
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large variability in gene expression, proliferative capacity, differentia-
tion capacity, and transfection efficacy between the donor and tissue
source from which they were obtained;13–15,24,50,54 however, these pa-
rameters have not been studied in depth as they pertain to DNA vec-
tor modifications and transfection outcomes.13,14 Here, the data show
discrepancies in trends between transfection outcomes for each con-
dition between the different donors and tissue sources (Figure 2),
which may be partly attributed to the different proliferation rates be-
tween hMSCs from different donors and tissue source.50 Generally,
hAMSCs have higher proliferation rates compared to hBMSCs,50
which may increase nuclear internalization of DNA vectors due to
the increased nuclear breakdown, thereby giving hAMSCs a higher
probability of successful transfection compared to hBMSCs. The
slower proliferating hBMSCs may have lower probabilities of success-
ful transfection due to less nuclear breakdown but have a higher DNA
vector-to-cell ratio due to their lower cell numbers compared to
hAMSCs (Figure 6), possibly causing an increase in transfection-
induced toxicity (Figure S4) due to the higher DNA vector dose, as
others have observed.55 However, further studies are needed in order
to elucidate the discrepancies in transfection efficiency and transgene
expression observed in this study between different conditions on a
hMSC donor and tissue source basis.
Conclusions
This work systematically investigated the effects of DNA vector mod-
ifications (i.e., promoter, bacterial element quantities, and positions
within the vector) on transfection in hMSCs from different donors
and tissue sources using two commercially available cationic carriers.
Analyzing each variable separately, we observed differences in trans-
fection outcomes based on promoter selection, DNA vector, and
cationic carrier, as well as donor and tissue source. Notably, we
observed the highest levels of transgene expression when MIPs, com-
plexed with Lipofectamine 3000, were delivered to hAMSCs and
transgene production was under control of the CMV promoter.
Furthermore, the presented data provide valuable insight into the
importance of hMSC donor and tissue source variability as they
pertain to DNA vector modifications for nonviral gene delivery.
This work demonstrates that transfection parameters may need to
be tuned in an application- and patient-specific manner in order to
achieve efficient transfection in hMSCs for clinical therapies.
MATERIALS AND METHODS
Cell culture
Cryopreserved hMSCs from four human donors and two tissue sour-
ces were purchased at passage two from Lonza (Lonza, Walkersville,
MD, USA) and were used at passage six (see Table S1 for donor infor-
mation). Adipose-derived hMSCs (hAMSCs) were positive for CD13,
CD29, CD44, CD73, CD90, CD105, CD166, and negative for CD14,
CD31, and CD45 cell surface markers. Bone-marrow-derived hMSCs
(hBMSCs) were positive for CD29, CD44, CD105, and CD166 and
negative for CD14, CD34, and CD45 cell surface markers. hMSCs
were passaged and cultured in hMSC media, consisting of minimum
essential medium alpha (MEM Alpha; GIBCO, Grand Island, NY,
USA) supplemented with 10% heat-inactivated fetal bovine serum
(FBS; GIBCO), 6 mM L-Glutamine (GIBCO), and 1% penicillin-
streptomycin (Pen-Strep; 10,000 U/mL; GIBCO), and incubated at
37C with 5% CO2 until confluent. At confluence, hMSC media
was removed and cells were washed with 1 phosphate-buffered
saline (PBS) prior to the addition of 0.25% trypsin-ethylenediamine
tetraacetic acid (EDTA; GIBCO) for cellular dissociation. After disso-
ciation, an equal volume of hMSC media was added and total cellular
suspension was removed for subsequent cell pelleting via
Figure 6. Transgene expression data as a function
of hMSC tissue source and donor
(A) Scatterplot showing aggregated EGFP-positive cells
and total cell counts for all transfection conditions in both
donors of adiposed-derived hMSCs (hAMSCs). (B) Scat-
terplot showing aggregated EGFP-positive cells and total
cell counts for all transfection conditions in both donors of
bone-marrow-derived hMSCs (hBMSCs). Q1 represents
high transgene expression but low total cell counts, which
could be attributed to either transfection-induced toxicity
and/or a reduction in proliferation. Q2 represents high
transgene expression with high total cell counts, which
could be attributed to either minimal transfection-induced
toxicity and/or minimal reduction in proliferation. Q3 rep-
resents both low transgene expression and low total cell
counts. Lastly, Q4 represents low transgene expression
but high total cell counts. It should be noted that these
quadrants were partitioned using the highest number
of EGFP-positive cells and total cell counts that were
observed in this current study; therefore, these quadrant
boundaries should not be used to evaluate conditions and
data from other studies. Lines represent the Poisson
regression line that best fits the data. Parameters are
identified within the legend provided.
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centrifugation to remove trypsin-EDTA. Cells were resuspended in
warm hMSCmedia and counted via trypan blue exclusion using a he-
mocytometer prior to diluting in hMSC media for seeding, as
described next.
For seeding of hAMSCs, cells were dissociated and counted, as
described above, and 100 mL of 4.5  104 cells/mL cell suspension
(4,500 cells/well; D1 and D2) was added to each well of clear bottom,
black walled, 96-well plates (Corning Life Sciences, Corning, NY,
USA). Immediately following seeding, plates were incubated at
37C and 5% CO2 and allowed to culture for 24 h. For seeding of
hBMSCs, cells were dissociated and counted, as described above,
and 100 mL of 4  104 cells/mL cell suspension (4,000 cells/well;
D3 & D4) was added to each well of clear bottom, black walled, 96-
well plates (Corning Life Sciences). Immediately following seeding,
plates were incubated at 37C and 5% CO2 and allowed to culture
for 48 h. The different seeding densities and culture times for
hAMSCs (4.5  104 cells/mL, 24 h) and hBMSCs (4  104 cells/
mL, 48 hours) were selected so all experimental conditions were at
80% confluence before transfecting, as described below.
DNA vectors
All DNA vectors used in this screen encode for a fusion protein of
EGFP and firefly luciferase (EGFPLuc, Figure 1 and Table 1).
pTubb3-MC was a gift from Juan Belmonte (Addgene plasmid
#87112; http://n2t.net/addgene:87112; RRID: Addgene_87112)56
and was used to clone minicircle (MC) vectors MC.EGFPLuc-
CMV, MC.EGFPLuc-EF1a, and MC.Expressionless (Genscript, Pis-
cataway, NJ, USA). MIP 247 CoMIP 4in1 with shRNA p53 was a
gift from Mark Kay and Joseph Wu (Addgene plasmid #63726;
http://n2t.net/addgene:63726; RRID: Addgene_63726)22 and was
used to clone MIP vectors MIP.EGFPLuc-CMV, MIP.EGFPLuc-
EF1a, and MIP.Expressionless (Genscript). The F1 origin of replica-
tion was removed from EGFPLuc-CMV (Clontech, Mountain
View, CA, USA) and pEGFPLuc-EF1a (Genscript) in order to clone
pEGFPLuc-CMV No F1 and pEGFPLuc-EF1a No F1, respectively
(Genscript). MC vectors (MC.EGFPLuc-CMV, MC.EGFPLuc-EF1a,
and MC.Expressionless) were propagated in the bacterial strain
ZYCY10P3S2T (System Biosciences, Palo Alto, CA) under kana-
mycin selection following a published protocol,57 with minor
changes. Briefly, 100 mL of Terrific Broth (TB; Invitrogen) was inoc-
ulated with bacterial strain ZYCY10P3S2T containing MC vectors
and cultured overnight at 37C with shaking at 250 RPM. The
overnight culture was then mixed with minicircle induction mix
comprising 100 mL of Luria-Bertani broth (LB; Becton Dickinson,
Franklin Lakes, NJ, USA), 4 mL of 1N NaOH, and 100 mL of 20%
L-arabinose, and cultured for 5 h at 32C with shaking at 250
RPM. All MIP vectors (MIP.EGFPLuc-CMV, MIP.EGFPLuc-EF1a,
and MIP.Expressionless) were propagated in RNA-OUT competent
cells (Nature Technologies, Lincoln, NE, USA)58 using 6% sucrose se-
lection media. All plasmids (pEGFPLuc-CMV, pEGFPLuc-CMV No
F1, pEGPFLuc-EF1a, and pEGFPLuc-EF1a) were propagated in
DH5a e. coli. (Invitrogen, Carlsbad, CA, USA) under kanamycin se-
lection. All DNA vectors were isolated and purified using a Purelink
High Purity Endotoxin free plasmid purification kit (Invitrogen).
DNA quality and yield were measured using a Nanodrop (Thermo
Fisher Scientific) and all DNA vectors were resuspended in Tris
EDTA (TE) buffer at a concentration of 1 mg/mL.
In order to compare DNA vectors, an equal amount of transgene (i.e.,
molarity of expression cassette) and DNA mass was delivered to
hMSCs for each DNA vector. Molarity of expression cassette for
each DNA vector was normalized by dividing the size of each DNA
vector (in kilobase pairs) by the size of the largest DNA vector (in
kilobase pairs) for each promoter. DNA mass was then equalized
by adding the remaining fraction of corresponding expressionless
vector to make all DNA vector stocks be 1 mg/mL (Table 2).
hMSC transfection
24 h after seeding of hAMSCs, or 48 h after seeding of hBMSCs, as
described above, all DNA vectors were complexed with either Lipo-
fectamine 3000 (Invitrogen) at a DNA:lipid ratio of 1:2 in serum
free Opti-MEMmedia (Invitrogen) following themanufacturer’s pro-
tocol or complexed with Turbofect (Thermo Fisher Scientific) at a
DNA:polymer ratio of 1:4 in serum free Opti-MEM media following
manufacturer’s protocol. After complex formation, 0.07 mg of Lipo-
fectamine 3000 complexed DNA vector in 6.7 mL of Opti-MEM or
0.07 mg of Turbofect complexed DNA vector in 11.1 mL of Opt-
MEM was delivered to each well, and plates were briefly centrifuged
to ensure mixing of complexes with the hMSC media. Media were
removed immediately after centrifugation and replaced with fresh,
warmed, hMSC media lacking complexes. Following complex deliv-
ery, hMSCs were placed into incubators at 37C and 5% CO2 and al-
lowed to culture for 48 h.
Cell staining and high content imaging for transfection
efficiency assessment
48 h after delivery of complexes, cells were stained with Hoechst
33342 (Sigma-Aldrich, St. Louis, MO, USA) to enable nuclei counts
for assessment of EGFP transfection efficiencies. After removing cul-
ture media from the cells, 50 mL of staining solution (1 mg/mL of
Hoechst in hMSC media) was added to each well and incubated for
25 min at 37C and 5% CO2. After incubation, staining solution
was removed, and cells were rinsed with 20 mL of 1 PBS on a
multi-purpose rotator for 5 min, after which the rinse was removed
and 100 mL of 1 PBS was added to each well for subsequent imaging.
Images of each well were acquired with a Cytation 1 Cell Imaging Sys-
tem (Biotek, Winooski, VT, USA), equipped with a laser autofocus
cube and GFP (EGFP transgene production) and DAPI (nuclei count
via Hoechst) filter cubes paired with 465 nm and 365 nm LED cubes,
respectively. Two images, spaced 150 mm apart vertically, were taken
of each well in each fluorescent channel, in addition to phase contrast
images, using a 4 objective. Consistent fluorescence excitation LED
intensity and camera exposure settings were used to allow for com-
parison of image intensities between wells in the same plate. After im-
aging, cells were washed with PBS and lysed with 150 mL per well of
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1 reporter lysis buffer (Promega, Madison, WI, USA) by incubating
at room temp for 10 min prior to storage at 80C.
Assessment of transfection efficiency and transgene expression
levels
Gen5 software (Biotek) was used for image preprocessing and decon-
volution (to subtract background fluorescence from captured digital
images), as well as object analysis (e.g., EGFP-positive cells and cell
nuclei) in order to calculate transfection efficiencies. Object analysis
identified objects of interest in all channels by their fluorescence in-
tensity and size. DAPI and GFP intensity thresholds were set at
5,000 and 1,000 relative fluorescent units (RFUs), respectively, and
minimum and maximum object size were set at 12 and 50 (DAPI)
and 12 and 150 (GFP).
Transfection efficiency was calculated by dividing the number of
EGFP objects (cells producing transgene) by the number of DAPI ob-
jects (cell nuclei) in the same well. Transgenic luciferase activity levels
were quantified by measuring luciferase luminescence in RLUs with a
Luciferase Assay kit (Promega) and a luminometer (Turner Designs,
Sunnyvale, CA, USA). RLUs were normalized to total protein amount
determined with a Pierce bicinchoninic acid (BCA) colorimetric assay
(Pierce, Rockford, IL, USA) using an Epoch plate reader (Biotek) to
measure absorbance at 562 nm.
Quantification of transgenic mRNA
To quantify relative mRNA transcript copy numbers of the EGFPLuc
transgene from each DNA vector, we seeded D6 hAMSCs at 4.5 104
cells/mL (4,500 cells/well), as described above, and cultured at 37C
and 5% CO2. 24 h after seeding, D1 hAMSCs were transfected with
DNA vectors complexed with Turbofect transfection reagent, as
described above. 12 and 24 h following transfection, mRNA was iso-
lated for each condition using SingleShot Cell Lysis Kit (Bio-Rad,
Hercules, CA, USA) following the manufacturer’s protocol. Isolated
mRNA was then reverse transcribed using iScript cDNA Synthesis
Kit (Bio-Rad) following the manufacturer’s protocol. qRT-PCR was
performed on a QuantStudio 6 Flex Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) with Power SYBR Green Master
Mix (Thermo Fisher Scientific) and relative expression was calculated
by the DDCt method normalizing to the endogenous control
RPL13A. See Table S2 for primer sequences (Integrated DNA Tech-
nologies, Coralville, IA, USA).
Data analysis and statistics
In this study, two promoters in eight DNA vectors complexed with
two commercially available transfection reagents were investigated
in four donors of hMSCs from two tissue sources (64 conditions).
Our experimental design for this study was a split-plot design with
the whole plot factor being the cationic carrier and the split plot factor
being vector  promoter after blocking by donor. All data are re-
ported as the mean of triplicate values for each condition on duplicate
days (n = 6), except where noted. In order to compare each variable
tested, the EGFP cell counts and total cell counts for all 64 conditions
tested (Figure 2) were aggregated for that particular variable and pre-
sented in scatterplots (Figures 3, 4, 5, and 6) divided into four quad-
rants. Q1 represents high transgene expression but low total cell
counts (which could be attributed to either transfection-induced
toxicity and/or a reduction in proliferation). Q2 represents high
transgene expression with high total cell counts (which could be
attributed to either minimal transfection-induced toxicity and/or
minimal reduction in proliferation). Q3 represents both low trans-
gene expression and low total cell counts. Lastly, Q4 represents low
transgene expression but high total cell counts. It should be noted
that these quadrants were partitioned using the highest number of
EGFP-positive cells and total cell counts that were observed in this
current study; therefore, these quadrant boundaries should not be
used to evaluate conditions and data from other studies. Poisson re-
gressions, with the line forced through the origin, were performed for
each scatterplot (i.e., variable) in order to visually identify differences
in EGFP cell counts versus total cell counts for each variable tested.
EGFP-positive cell count data represented in the scatterplots were
analyzed as a negative binomial variable with the total cell counts
as an offset term. Kenward-Roger adjustment was used on the degrees
of freedom to account for the multiple error levels in the analysis.
Transfection efficiency and transgenic luciferase activity fold changes
were calculated for all pairwise comparisons for each donor by
dividing the six transgene expression values for each column condi-
tion by the average (n = 6 for each condition) of the row condition
(Figures S1 and S2). Relative transgenic mRNA transcript fold-
changes were analyzed using an ANOVA with Dunnett’s post hoc
test. Statistical significance was accepted for p values less than 0.05.
Statistics were evaluated using Prism GraphPad software (GraphPad
Software, La Jolla, CA, USA) and SAS/STAT 14.2 software, version
9.4 of the SAS system for Windows. Copyright 2016 SAS Institute
SAS and all other SAS Institute product or service names are regis-
tered trademarks or trademarks of SAS Institute (SAS Institute,
Cary, NC, USA).
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Table S1: hMSC Donor Information 
Donor ID Tissue Source Age Sex Ethnicity/Race 
D1 Adipose 22 M Black 
D2 Adipose 42 F Black 
D3 Bone Marrow 22 M Not provided 
D4 Bone Marrow 31 M Black 
 
Table S2: Sequences of Primers Used in qRT-PCR 
EGFP Forward 5’-ACGTAAACGGCCACAAGTTC-3’ 
EGFP Reverse 5’-AAGTCGTGCTGCTTCATGTG-3’ 
RPL-13A Forward 5’-CCTGGAGGAGAAGAGGAAAGAGA-3’ 
RPL-13A Reverse 5’-TTGAGGACCTCTGTGTATTTGTCAA-3’ 
 
 
Table S4: Pairwise Comparisons Between Promoters for Each Vector 
Vector Promoter _Promoter Estimate SE DF t Value Pr > |t| Adj P 
Plasmid CMV EF1a 1.8122 0.09838 353 18.42 <.0001 <.0001 
No F1 CMV EF1a 1.9739 0.09191 316 21.48 <.0001 <.0001 
MC CMV EF1a 1.8122 0.09838 353 18.42 <.0001 <.0001 
MIP CMV EF1a 1.1076 0.08760 262.6 12.64 <.0001 <.0001 
EGFP positive cell counts for each promoter were analyzed as a negative binomial with total cell count 
as an offset term.  Promoter effects within each vector were compared using least square means with use 
of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the 
estimated responses for each promoter; SE, standard error; DF, degrees of freedom; t value, t-test 
statistic; Pr > |t|, p-value associated with the t statistic; Adj P, adjusted p-value.  Significance was 
accepted at p<0.05.   
 
  
Table S3: Type III Tests of Fixed Effects 
Effect DF Den DF F Value Pr > F 
Cationic Carrier 1 4.134 15.05 0.0168 
Donor 3 4.001 10.12 0.0244 
Promoter 1 330.7 1455.64 <.0001 
Vector 3 326 186.99 <.0001 
Cationic Carrier*Donor 3 4.047 12.85 0.0156 
Cationic Carrier*Promoter 1 321.4 85.87 <.0001 
Cationic Carrier*Vector 3 310.9 8.16 <.0001 
Donor*Promoter 3 321 18.07 <.0001 
Donor*Vector 9 310 13.37 <.0001 
Promoter*Vector 3 325.5 27.72 <.0001 
EGFP positive cell counts for each effect (variable) were analyzed as a negative binomial with total cell 
count as an offset term.  Kenward-Rogers adjustment was used on the degrees of freedom to account for 
the multiple error levels in our analysis.  DF, degrees of freedom; Den DF, degrees of freedom associated 
with model errors; F-Value, F-test statistic; Pr > F, p-value associated with the F statistic. Significance 
was accepted at p<0.05. 
Table S5: Pairwise Comparisons Between Promoters for Each Cationic Carrier 
Cationic Carrier Promoter _Promoter Estimate SE DF t Value Pr > |t| 
Turbofect CMV EF1a 2.2020 0.06665 345.7 33.04 <.0001 
Lipofectamine CMV EF1a 1.3440 0.06453 306.8 20.83 <.0001 
EGFP positive cell counts for each promoter were analyzed as a negative binomial with total cell count 
as an offset term.  Promoter effects within each cationic carrier were compared using least square means 
with use of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between 
the estimated responses for each promoter; SE, standard error; DF, degrees of freedom; t value, t-test 
statistic; Pr > |t|, p-value associated with the t statistic.  Significance was accepted at p<0.05. 
 
Table S6: Pairwise Comparisons Between Promoters for Each Donor 
Donor Promoter _Promoter Estimate SE DF t Value Pr > |t| Adj P 
D1 CMV EF1a 1.2843 0.09338 331.9 13.75 <.0001 <.0001 
D2 CMV EF1a 1.6203 0.09204 311.3 17.61 <.0001 <.0001 
D3 CMV EF1a 2.0922 0.09429 347.6 22.19 <.0001 <.0001 
D4 CMV EF1a 2.0951 0.09100 304.5 23.02 <.0001 <.0001 
EGFP positive cell counts for each promoter were analyzed as a negative binomial with total cell count 
as an offset term.  Promoter effects within each donor were compared using least square means with use 
of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the 
estimated responses for each promoter; SE, standard error; DF, degrees of freedom; t value, t-test 
statistic; Pr > |t|, p-value associated with the t statistic; Adj P, adjusted p-value.  Significance was 
accepted at p<0.05.   
 
Table S7: Pairwise Comparisons Between Vectors for Each Promoter 
Promoter Vector _Vector Estimate SE DF t Value Pr > |t| Adj P 
CMV MC MIP -1.1961 0.08807 268.2 -13.58 <.0001 <.0001 
CMV MC No F1 -0.8637 0.08838 272 -9.77 <.0001 <.0001 
CMV MC Plasmid -0.8924 0.08863 275 -10.07 <.0001 <.0001 
CMV MIP No F1 0.3324 0.08651 250.1 3.84 0.0002 0.0009 
CMV MIP Plasmid 0.3036 0.08677 253 3.50 0.0006 0.0031 
CMV No F1 Plasmid -0.02875 0.08708 256.7 -0.33 0.7415 0.9876 
EF1a MC MIP -1.9006 0.09797 353 -19.40 <.0001 <.0001 
EF1a MC No F1 -0.7020 0.1016 353 -6.91 <.0001 <.0001 
EF1a MC Plasmid -0.5063 0.1026 353 -4.93 <.0001 <.0001 
EF1a MIP No F1 1.1987 0.09291 329.2 12.90 <.0001 <.0001 
EF1a MIP Plasmid 1.3943 0.09413 347.9 14.81 <.0001 <.0001 
EF1a No F1 Plasmid 0.1956 0.09785 353 2.00 0.0463 0.1901 
EGFP positive cell counts for each vector were analyzed as a negative binomial with total cell count as 
an offset term.  Vector effects within each promoter were compared using least square means with use 
of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the 
estimated responses for each vector; SE, standard error; DF, degrees of freedom; t value, t-test statistic; 
Pr > |t|, p-value associated with the t statistic; Adj P, adjusted p-value.  Significance was accepted at 
p<0.05.  Red highlighted adjusted p-values indicate no significant difference at α=0.05 
  
Table S8: Pairwise Comparisons Between Vectors for Each Cationic Carrier 
Cationic Carrier Vector _Vector Estimate SE DF t Value Pr > |t| Adj P 
Turbofect MC MIP -1.5044 0.09400 336.9 -16.00 <.0001 <.0001 
Turbofect MC No F1 -0.5944 0.09662 353 -6.15 <.0001 <.0001 
Turbofect MC Plasmid -0.8299 0.09659 353 -8.59 <.0001 <.0001 
Turbofect MIP No F1 0.9100 0.09115 303 9.98 <.0001 <.0001 
Turbofect MIP Plasmid 0.6745 0.09114 303.4 7.40 <.0001 <.0001 
Turbofect No F1 Plasmid -0.2355 0.09386 336.1 -2.51 0.0126 0.0604 
Lipofectamine 3000 MC MIP -1.5923 0.09171 312.6 -17.36 <.0001 <.0001 
Lipofectamine 3000 MC No F1 -0.9712 0.09288 327.9 -10.46 <.0001 <.0001 
Lipofectamine 3000 MC Plasmid -0.5689 0.09420 345.3 -6.04 <.0001 <.0001 
Lipofectamine 3000 MIP No F1 0.6211 0.08815 268.8 7.05 <.0001 <.0001 
Lipofectamine 3000 MIP Plasmid 1.0235 0.08956 285.5 11.43 <.0001 <.0001 
Lipofectamine 3000 No F1 Plasmid 0.4023 0.09078 300.4 4.43 <.0001 <.0001 
EGFP positive cell counts for each vector were analyzed as a negative binomial with total cell count as 
an offset term.  Vector effects within each cationic carrier were compared using least square means with 
use of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the 
estimated responses for each vector; SE, standard error; DF, degrees of freedom; t value, t-test statistic; 
Pr > |t|, p-value associated with the t statistic; Adj P, adjusted p-value.  Significance was accepted at 
p<0.05.  Red highlighted adjusted p-values indicate no significant difference at α=0.05 
  
Table S9: Pairwise Comparisons Between Vectors for Each Donor 
Donor Vector _Vector Estimate SE DF t Value Pr > |t| Adj P 
D1 MC MIP -1.7418 0.1318 329.4 -13.22 <.0001 <.0001 
D1 MC No F1 -0.3901 0.1353 353 -2.88 0.0042 0.0216 
D1 MC Plasmid -0.2420 0.1367 353 -1.77 0.0777 0.2898 
D1 MIP No F1 1.3517 0.1267 283.9 10.67 <.0001 <.0001 
D1 MIP Plasmid 1.4998 0.1283 298.4 11.69 <.0001 <.0001 
D1 No F1 Plasmid 0.1481 0.1320 328.4 1.12 0.2624 0.6758 
D2 MC MIP -2.3004 0.1325 328.6 -17.37 <.0001 <.0001 
D2 MC No F1 -1.5455 0.1338 340.6 -11.55 <.0001 <.0001 
D2 MC Plasmid -1.2590 0.1355 353 -9.29 <.0001 <.0001 
D2 MIP No F1 0.7549 0.1242 264.7 6.08 <.0001 <.0001 
D2 MIP Plasmid 1.0413 0.1261 279.8 8.26 <.0001 <.0001 
D2 No F1 Plasmid 0.2864 0.1277 292.2 2.24 0.0256 0.1142 
D3 MC MIP -1.3379 0.1328 335 -10.08 <.0001 <.0001 
D3 MC No F1 -0.8160 0.1355 353 -6.02 <.0001 <.0001 
D3 MC Plasmid -0.7892 0.1362 353 -5.79 <.0001 <.0001 
D3 MIP No F1 0.5220 0.1286 299.5 4.06 <.0001 0.0004 
D3 MIP Plasmid 0.5488 0.1294 306.3 4.24 <.0001 0.0002 
D3 No F1 Plasmid 0.02683 0.1323 329 0.20 0.8394 0.9970 
D4 MC MIP -0.8133 0.1273 290.7 -6.39 <.0001 <.0001 
D4 MC No F1 -0.3797 0.1298 310.1 -2.92 0.0037 0.0193 
D4 MC Plasmid -0.5073 0.1296 309.4 -3.91 0.0001 0.0006 
D4 MIP No F1 0.4336 0.1269 284.9 3.42 0.0007 0.0040 
D4 MIP Plasmid 0.3060 0.1267 284.4 2.42 0.0164 0.0765 
D4 No F1 Plasmid -0.1276 0.1292 303.2 -0.99 0.3240 0.7565 
EGFP positive cell counts for each vector were analyzed as a negative binomial with total cell count 
as an offset term.  Vector effects within each donor were compared using least square means with 
use of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between 
the estimated responses for each vector; SE, standard error; DF, degrees of freedom; t value, t-test 
statistic; Pr > |t|, p-value associated with the t statistic; Adj P, adjusted p-value.  Significance was 
accepted at p<0.05.  Red highlighted adjusted p-values indicate no significant difference at α=0.05 
 
Table S10: Pairwise Comparisons Between Cationic Carriers for Each Promoter 
Promoter Cationic Carrier _Cationic Carrier Estimate SE DF t Value Pr > |t| Adj P 
CMV Lipofectamine 3000 Turbofect -0.2017 0.07151 9.14 -2.82 0.0197 0.0197 
EF1a Lipofectamine 3000 Turbofect 0.6563 0.07772 12.74 8.45 <0.0001 <0.0001 
EGFP positive cell counts for each cationic carrier were analyzed as a negative binomial with total cell count as an 
offset term.  Cationic carrier effects within each promoter were compared using least square means with use of Tukey-
Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the estimated responses for each 
cationic carrier; SE, standard error; DF, degrees of freedom; t value, t-test statistic; Pr > |t|, p-value associated with 
the t statistic.  Significance was accepted at p<0.05.   
 
  
Table S11: Pairwise Comparisons Between Cationic Carriers for Each Vector 
Vector Cationic Carrier _Cationic Carrier Estimate SE DF t Value Pr > |t| Adj P 
Plasmid Lipofectamine 3000 Turbofect -0.08462 0.09949 32.95 -0.85 0.4012 0.4012 
No F1 Lipofectamine 3000 Turbofect 0.5532 0.09832 31.46 5.63 <0.0001 <0.0001 
MC Lipofectamine 3000 Turbofect 0.1764 0.1038 38.9 1.7 0.0971 0.0971 
MIP Lipofectamine 3000 Turbofect 0.2643 0.09460 26.99 2.79 0.0095 0.0095 
EGFP positive cell counts for each cationic carrier were analyzed as a negative binomial with total cell count as an 
offset term.  Cationic carrier effects within each vector were compared using least square means with use of Tukey-
Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the estimated responses for each 
cationic carrier; SE, standard error; DF, degrees of freedom; t value, t-test statistic; Pr > |t|, p-value associated with 
the t statistic.  Significance was accepted at p<0.05.  Red highlighted p-values indicate no significant difference at 
α=0.05. 
 
Table S12: Pairwise Comparisons Between Cationic Carriers for Each Donor 
Donor Cationic Carrier _Cationic Carrier Estimate SE DF t Value Pr > |t| 
D1 Lipofectamine Turbofect 0.5510 0.1174 4.157 4.69 0.0085 
D2 Lipofectamine Turbofect 0.6193 0.1163 4.006 5.33 0.0060 
D3 Lipofectamine Turbofect -0.2048 0.1177 4.214 -1.74 0.1534 
D4 Lipofectamine Turbofect -0.05621 0.1155 3.906 -0.49 0.6526 
EGFP positive cell counts for each cationic carrier were analyzed as a negative binomial with total cell 
count as an offset term.  Cationic carrier effects within each donor were compared using least square means 
with use of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the 
estimated responses for each cationic carrier; SE, standard error; DF, degrees of freedom; t value, t-test 
statistic; Pr > |t|, p-value associated with the t statistic.  Significance was accepted at p<0.05.  Red 






Table S13: Pairwise Comparisons Between Donors for Each Promoter 
Promoter Donor _Donor Estimate SE DF t Value Pr > |t| Adj P 
CMV D1 D2 -0.6892 0.2325 4.565 -2.96 0.0351 0.1143 
CMV D1 D3 -1.2501 0.2325 4.566 -5.38 0.0039 0.0141 
CMV D2 D3 -0.5609 0.2322 4.546 -2.42 0.0655 0.2012 
CMV D4 D1 1.5946 0.2323 4.553 6.86 0.0014 0.0053 
CMV D4 D2 0.9054 0.2321 4.533 3.9 0.0138 0.0474 
CMV D4 D3 0.3445 0.2321 4.534 1.48 0.2037 0.5133 
EF1a D1 D2 -0.3532 0.236 4.852 -1.5 0.1966 0.5041 
EF1a D1 D3 -0.4423 0.2369 4.923 -1.87 0.1218 0.3474 
EF1a D2 D3 -0.0891 0.2366 4.9 -0.38 0.7223 0.9798 
EF1a D4 D1 0.7838 0.2358 4.832 3.32 0.022 0.0752 
EF1a D4 D2 0.4306 0.2355 4.81 1.83 0.1293 0.3634 
EF1a D4 D3 0.3415 0.2364 4.879 1.44 0.2095 0.5285 
EGFP positive cell counts for each donor were analyzed as a negative binomial with total cell count as 
an offset term.  Donor effects within each promoter were compared using least square means with use of 
Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the estimated 
responses for each donor; SE, standard error; DF, degrees of freedom; t value, t-test statistic; Pr > |t|, p-
value associated with the t statistic; Adj P, adjusted p-value.  Significance was accepted at p<0.05.  Red 
highlighted adjusted p-values indicate no significant difference at α=0.05 
 
  
Table S14: Pairwise Comparisons Between Donors for Each Vector 
Vector Donor _Donor Estimate SE DF t Value Pr > |t| Adj P 
Plasmid D1 D2 -0.8555 0.2521 6.311 -3.39 0.0135 0.0509 
Plasmid D1 D3 -1.2511 0.2531 6.404 -4.94 0.0022 0.0088 
Plasmid D2 D3 -0.3956 0.252 6.3 -1.57 0.1652 0.4558 
Plasmid D4 D1 1.6229 0.252 6.298 6.44 0.0005 0.0023 
Plasmid D4 D2 0.7674 0.251 6.194 3.06 0.0214 0.0779 
Plasmid D4 D3 0.3718 0.2519 6.287 1.48 0.1882 0.5018 
No F1 D1 D2 -0.9938 0.2504 6.14 -3.97 0.007 0.0272 
No F1 D1 D3 -1.1298 0.2519 6.284 -4.49 0.0037 0.0148 
No F1 D2 D3 -0.136 0.2507 6.17 -0.54 0.6065 0.9454 
No F1 D4 D1 1.3472 0.2513 6.227 5.36 0.0015 0.0062 
No F1 D4 D2 0.3534 0.2501 6.113 1.41 0.2066 0.5351 
No F1 D4 D3 0.2174 0.2516 6.256 0.86 0.4195 0.8230 
MC D1 D2 0.1616 0.257 6.807 0.63 0.55 0.9195 
MC D1 D3 -0.7039 0.2565 6.754 -2.74 0.0298 0.1074 
MC D2 D3 -0.8655 0.2568 6.786 -3.37 0.0125 0.048 
MC D4 D1 1.3576 0.2541 6.506 5.34 0.0014 0.0056 
MC D4 D2 1.5192 0.2545 6.545 5.97 0.0007 0.003 
MC D4 D3 0.6537 0.2539 6.491 2.57 0.0393 0.1370 
MIP D1 D2 -0.397 0.2477 5.876 -1.6 0.1611 0.4438 
MIP D1 D3 -0.3001 0.2484 5.946 -1.21 0.2729 0.6446 
MIP D2 D3 0.09696 0.2484 5.941 0.39 0.7099 0.9780 
MIP D4 D1 0.4291 0.2481 5.915 1.73 0.1351 0.3875 
MIP D4 D2 0.03209 0.248 5.91 0.13 0.9013 0.9991 
MIP D4 D3 0.1291 0.2488 5.98 0.52 0.6226 0.9515 
EGFP positive cell counts for each donor were analyzed as a negative binomial with total cell count as 
an offset term.  Donor effects within each vector were compared using least square means with use of 
Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the estimated 
responses for each donor; SE, standard error; DF, degrees of freedom; t value, t-test statistic; Pr > |t|, p-
value associated with the t statistic; Adj P, adjusted p-value.  Significance was accepted at p<0.05.  Red 
highlighted adjusted p-values indicate no significant difference at α=0.05 
  
Table S15: Pairwise Comparisons Between Donors for Each Cationic Carrier 
Cationic Carrier Donor _Donor Estimate SE DF t Value Pr > |t| Adj P 
Turbofect D1 D2 -0.4871 0.2402 5.11 -2.03 0.0972 0.2897 
Turbofect D1 D3 -1.2241 0.2404 5.127 -5.09 0.0035 0.0132 
Turbofect D2 D3 -0.737 0.2402 5.113 -3.07 0.0271 0.0925 
Turbofect D4 D1 1.4928 0.2398 5.078 6.22 0.0015 0.0056 
Turbofect D4 D2 1.0057 0.2397 5.064 4.2 0.0083 0.0301 
Turbofect D4 D3 0.2687 0.2399 5.081 1.12 0.3127 0.6941 
Lipofectamine 3000 D1 D2 -0.5553 0.239 5.003 -2.32 0.0677 0.2113 
Lipofectamine 3000 D1 D3 -0.4683 0.2395 5.05 -1.96 0.1074 0.3142 
Lipofectamine 3000 D2 D3 0.08698 0.2391 5.02 0.36 0.7309 0.9817 
Lipofectamine 3000 D4 D1 0.8856 0.2389 5.003 3.71 0.0139 0.0492 
Lipofectamine 3000 D4 D2 0.3303 0.2386 4.973 1.38 0.2252 0.5576 
Lipofectamine 3000 D4 D3 0.4173 0.2391 5.019 1.74 0.1412 0.3926 
EGFP positive cell counts for each donor were analyzed as a negative binomial with total cell count as an 
offset term.  Donor effects within each cationic carrier were compared using least square means with use of 
Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the estimated 
responses for each donor; SE, standard error; DF, degrees of freedom; t value, t-test statistic; Pr > |t|, p-value 
associated with the t statistic; Adj P, adjusted p-value.  Significance was accepted at p<0.05.  Red highlighted 
adjusted p-values indicate no significant difference at α=0.05 
 
Figure S1. Donor specific transfection efficiency fold changes for all pairwise comparisons of transfection 
conditions.  (A) Transfection efficiency fold changes for all pairwise comparisons of transfection 
conditions in D1 hAMSCs.  (B) Transfection efficiency fold changes for all pairwise comparisons of 
transfection conditions in D2 hAMSCs.  (C) Transfection efficiency fold changes for all pairwise 
comparisons of transfection conditions in D3 hBMSCs.  (D) Transfection efficiency fold changes for all 




Figure S2. Donor specific transgenic luciferase activity fold changes for all pairwise comparisons of 
transfection conditions.  (A) Transgenic luciferase activity fold changes for all pairwise comparisons of 
transfection conditions in D1 hAMSCs.  (B) Transgenic luciferase activity fold changes for all pairwise 
comparisons of transfection conditions in D2 hAMSCs.  (C) Transgenic luciferase activity fold changes 
for all pairwise comparisons of transfection conditions in D3 hBMSCs.  (D) Transgenic luciferase activity 
fold changes for all pairwise comparisons of transfection conditions in D4 hBMSCs.  Fold changes are 
presented relative to column conditions.
 
Figure S3. Relative transgenic mRNA transcripts at 12- and 24-hours following delivery of complexes as a 
function of DNA vector and promoter.  (A) Transgenic mRNA transcripts, relative to the plasmid vector 
with the CMV promoter, for D1 hMSCs 12 hours after delivery of DNA vectors complexed with Turbofect.  
(B) Transgenic mRNA transcripts, relative to the plasmid vector with the EF1a promoter, for D1 hMSCs 
12 hours after delivery of DNA vectors complexed with Turbofect.  (C) Transgenic mRNA transcripts, 
relative to the plasmid vector with the CMV promoter, for D1 hMSCs 24 hours after delivery of DNA 
vectors complexed with Turbofect.  (D) Transgenic mRNA transcripts, relative to the plasmid vector with 
the EF1a promoter, for D1 hMSCs 24 hours after delivery of DNA vectors complexed with Turbofect.  Data 
in bar graphs are represented as mean ± SEM (n=6).  *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
  
Figure S4. Cationic carrier effects on total cell counts in different donors of hMSCs derived from adipose 
tissue and bone marrow.  Total cell counts for a DNA vector complexed with Turbofect were divided by 
total cell counts for the same DNA vector complexed with Lipofectamine 3000 for each donor to calculate 
total cell count ratios, which is an indirect measure of toxicity and/or proliferative effects of Turbofect 
relative to Lipofectamine 3000.  Data in bar graphs are represented as mean ± SEM (n=48/donor).  ****, 
p<0.0001 
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Humanmesenchymal stem cells (hMSCs) are primary cells with
high clinical relevance that could be enhanced through genetic
modification. However, gene delivery, particularly through
nonviral routes, is inefficient. To address the shortcomings of
nonviral gene delivery to hMSCs, our lab has previously
demonstrated that pharmacological “priming” of hMSCs
with clinically approved drugs can increase transfection in
hMSCs by modulating transfection-induced cytotoxicity. How-
ever, even with priming, hMSC transfection remains inefficient
for clinical applications. This work takes a complementary
approach to addressing the challenges of transfecting hMSCs
by systematically investigating key transfection parameters
for their effect on transgene expression. Specifically, we inves-
tigated two promoters (cytomegalovirus [CMV] and elonga-
tion factor 1 alpha), four DNA vectors (plasmid, plasmid
with no F1 origin, minicircle, and mini-intronic plasmid),
two cationic carriers (Lipofectamine 3000 and Turbofect),
and four donors of hMSCs from two tissues (adipose and
bone marrow) for efficient hMSC transfection. Following sys-
tematic comparison of each variable, we identified adipose-
derived hMSCs transfected with mini-intronic plasmids con-
taining the CMV promoter delivered using Lipofectamine
3000 as the parameters that produced the highest transfection
levels. The data presented in this work can guide the develop-
ment of other hMSC transfection systems with the goal of pro-
ducing clinically relevant, genetically modified hMSCs.
INTRODUCTION
Human mesenchymal stem cells (hMSCs) are under extensive
research for applications in cell and gene therapeutics1,2 due to their
ease of isolation frommultiple adult tissues,3 their multipotent differ-
entiation potential,4 and their ability to home to sites of injury and
reduce inflammation upon transplantation.5,6 These therapeutic
properties could be enhanced or expanded through genetic modifica-
tion accomplished via delivery of exogenous genes, e.g., delivery of a
DNA vector encoding for differentiation factors to enhance hMSC
tissue engineering applications.7 Genetic modification of hMSCs
can be accomplished via viral or nonviral methods.8,9 While viral
transduction is efficient, it suffers from safety issues related to immu-
nogenicity and insertional mutagenesis.9,10 Nonviral gene delivery,
which typically consists of condensing an anionic DNA vector with
a cationic carrier to form nano-sized complexes that are capable of
in vitro transfection,11 overcomes many challenges associated with
viral methods; however, nonviral gene delivery suffers from ineffi-
ciency, especially in hMSCs.12
To address the shortcomings of nonviral gene delivery to hMSCs, our
group has demonstrated that pharmacological “priming” of cells prior
to or simultaneously with application of nonviral DNA complexes
can improve transfection in hMSCs.13–16 Specifically, we have shown
that the glucocorticoid, dexamethasone, can significantly increase
transfection efficiency and transgene expression in multiple donors
of hMSCs from different tissues, relative to a vehicle control
(VC),13 by modulating transfection-induced stress pathways and
apoptosis.14,15 Additionally, we have expanded our hMSC transfec-
tion priming library by screening a collection of 707 FDA approved
drugs for drug repurposing17 and identified new candidate priming
agents that can significantly improve transfection compared to a
VC.16 However, even with priming, nonviral gene delivery to hMSCs
remains inefficient for clinical applications.
In addition to priming strategies to improve transfection in hMSCs,
research has shown that many factors can contribute to the success
of nonviral gene delivery systems, such as the promoter sequence,18
DNA vector,19–22 bacterial elements,19 cationic carrier,23 hMSC
donor,24 and hMSC tissue source.13–15 Two common promoters,
the viral cytomegalovirus (CMV) promoter and the endogenous elon-
gation factor 1 alpha (EF1a) promoter, have shown varying degrees of
transfection outcomes in hMSCs.14,25 For example, we have shown
increased transfection in hMSCs with a DNA vector containing the
viral CMV promoter compared to a DNA vector containing the
EF1a promoter,14 while others have shown the opposite in hMSCs
when using those promoters in different DNA vectors.25 In addition
to promoters, the DNA vectors themselves, and in particular the
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bacterial elements contained within the DNA vectors (e.g., bacterial
origins of replication, like the F1 origin,26 and antibiotic resistance
genes) can modulate transfection. For example, minicircle vectors
(MCs), which do not contain any bacterial elements, have shown
increased transfection efficiency in hMSCs compared to conventional
plasmids7 that contain bacterial elements. Alternatively, mini-in-
tronic plasmids (MIPs), which include bacterial elements within an
engineered intron, have shown enhanced transfection in vitro and
in vivo compared to conventional plasmids, possibly due to the inclu-
sion of an intron.19,22 However, MIPs have not been investigated in
the context of hMSC transfection. In addition to vector elements,
different cationic carriers, such as polymers or lipids, have shown
varying degrees of transfection in hMSCs.23 Beyond DNA vector
and cationic carrier, hMSC donor and tissue source (i.e., adipose or
bone marrow) can affect transfection success as well.13–15,24
However, even with the above studies, these variables and their effects
on nonviral gene delivery to hMSCs have yet to be systematically exam-
ined, and thus the objective of this work was to investigate four DNA
vectors (plasmid DNA, plasmid DNA with no F1 origin of replication,
MIPs, andMCs) and twopromoters (CMVandEF1a), complexedwith
two commercially available cationic carriers (Lipofectamine 3000 and
Turbofect) for their effects on transfection in hMSCs from four donors
derived from two tissue sources (adipose- and bone-marrow-derived).
This work systematically studies the key aspects of nonviral gene deliv-
ery systems as they pertain to hMSCs and offers insight into design pa-
rameters that can be exploited and further explored to develop efficient
gene delivery systems for cells of high clinical significance.
RESULTS
The objective of this study was to investigate the effects of different
promoters, DNA vectors, and cationic carriers on transfection in
hMSCs from different donors and tissues. Specifically, we investigated
two promoters (CMV and EF1a; Table 1) and four DNA vectors
(plasmid, plasmid with no F1 origin of replication, MC, and MIP; Ta-
ble 1; Figure 1), delivered using two commercially available cationic
carriers (Turbofect [polymer-mediated] and Lipofectamine 3000
[lipid-mediated]) to cells from four hMSC donors (D1, D2, D3, and
D4; Table S1) derived from two tissue sources (bone-marrow-derived
and adipose-derived; Table S1) in order to identify transfection pa-
rameters that significantly (p < 0.05) affect transfection efficiency
and transgene production in hMSCs. The effects on transfection effi-
ciency were assayed by fluorescence imaging of an expressed trans-
genic fusion protein of enhanced green fluorescent protein (EGFP)
with luciferase, normalized by total cell count (Hoechst 33342, nuclei
stain), to obtain transfection efficiencies for all conditions. Imaging
results were then verified by a chemical assay for transgenic luciferase
activity, in relative light units (RLUs), normalized by total cellular
protein values (RLU/mg Protein). It is important to note that due
to the varying sizes of DNA vectors and promoters tested, both
mass of DNA delivered and DNA copy number (i.e., molarity of
transgene) were normalized for each promoter and cationic carrier
in order to properly compare conditions (Table 2).
Given all of the variables above, this study tested 64 conditions, in trip-
licate on duplicate days (n = 6), to identify key transfection parameters
(Tables 1; Table S1) that modulate hMSC transfection efficiency (Fig-
ures 2A and 2C) and transgene production (Figures 2B and 2D). Both
outcomes varied widely as a function of each parameter, e.g., D3
bone-marrow-derived hMSCs (hBMSCs) transfected with the conven-
tional CMV plasmid complexed with Turbofect produced transfection
efficiencies around 35%, the highest of our study (Figure 2A), while D2
adipose-derived hMSCs (hAMSCs) transfected with CMV MIP com-
plexed with Lipofectamine 3000 produced the highest transgenic lucif-
erase activity of our study (Figure 2D). When comparing fold change
differences between all possible comparisons (Figures S1 and S2), D1
hAMSCs transfected with EF1a MIP vectors complexed with Lipofect-
amine 3000 increased transfection efficiency almost 2-fold and trans-
genic luciferase activity by more than 6-fold compared to D1 hAMSCs
transfected with the conventional CMV plasmid complexed with Lipo-
fectamine 3000 (Figures S1A andS2A, respectively).However, given the
multitude of parameters and combinations studied, data analysis was
performed to assess whether there were any significant interactions be-
tween variables. Analyzing the transfection data as a negative binomial
identified all two-way interactions as significant (Table S3), therefore,
further analysis of the effects of each individual parameter on transfec-
tion outcomes was conducted, as described next.
Promoter selection can affect transfection in hMSCs
In order to understand promoter effects on hMSC transfection, trans-
gene expression data (i.e., number EGFP-positive cells and total cells
counts) were grouped by promoter (CMV or EF1a) for all hMSCs
(D1, D2, D3, and D4), cationic carriers (Turbofect and Lipofectamine
3000), and DNA vectors (plasmid, no F1, MC, andMIP) and depicted
as scatterplots of total cell counts versus number of EGFP-positive
cells (Figure 3). These plots were sectioned into four quadrants for
each promoter as described in the methods and legend for Figure 3.
Analyzing transfection data as a function of promoter revealed differ-
ences between the CMV and EF1a promoters, as the CMV promoter
resulted in eight conditions (transfection efficiencies for conditions in
which hAMSCs were transfected with MIPs; Figure 3A) out of 192 to-
tal conditions/replicates in quadrant 2 (Q2; i.e., high transgene
expression and low total cell counts), whereas the EF1a promoter
Table 1. DNA vector information




CMV pUC origin of replication
EF1a
EF1a F1 origin of replication
Kanamycin resistance marker
CMV No F1 CMV pUC origin of replication




MIP CMV CMV pUC origin of replication
MIP EF1a EF1a RNA-OUT selectable marker
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resulted in no conditions in Q2 (Figure 3B). Furthermore, both pro-
moters resulted in a majority of the transfection conditions within Q3
(i.e., low transgene expression and low total cell counts). Analyzing
EGFP-positive cell counts as a negative binomial variable, with total
cell counts as an offset term, showed that in terms of promoter effects,
the CMV promoter resulted in significantly higher EGFP-positive cell
counts than the EF1a promoter at the same total cell count within vec-
tor (p < 0.0001, Table S4), cationic carrier (p < 0.0001, Table S5), and
donor (p < 0.0001, Table S6).
DNA vector bacterial elements affect transfection in hMSCs
In a similar manner used to compare promoters, transgene expression
data (i.e., number of EGFP-positive cells and total cell counts) were
grouped by the bacterial elements contained within each DNA vector
(Table 1; Figure 4). Transgene expression data for the 16 conventional
plasmid conditions, which contain the most bacterial elements (Table
1), were analyzed (i.e., CMV and EF1a; Table 1; Figure 2). Conditions
in which hMSCs were transfected with conventional plasmids gener-
ally had transgene expression data in Q3 (i.e., low transgene expres-
sion and low total cell counts; Figure 4A). Removal of the F1 origin
of replication from the conventional plasmid (No F1) resulted in
more transfection conditions with higher EGFP-positive cell counts
(i.e., Q1, more transgene expression) or higher total cell counts (i.e.,
Q4; Figure 4B) compared to conventional plasmids; however, condi-
tions in which hMSCs were transfected with No F1 vectors generally
had transgene expression data within Q3 (Figure 4B). Transgene
expression data for the 16 MC conditions were also analyzed (Table
1; Figure 2). Conditions in which hMSCs were transfected with
MCs generally produced transgene expression data that were within
Q3 (i.e., low transgene expression and low total cell counts; Fig-
ure 4C). Conditions where hMSCs were transfected with MCs also
produced a lower number of EGFP-positive cells (Figure 4C)
compared to conditions where hMSCs were transfected with either
conventional plasmids or No F1 vectors (Figures 4A and 4B, respec-
tively). Finally, the transgene expression data for the 16 MIP condi-
tions (Table 1; Figure 2) were analyzed. Conditions in which hMSCs
were transfected with MIPs generally produced transgene expression
data that were within Q3 (i.e., low transgene expression and low total
cell counts; Figure 4D); however, conditions where hMSCs were
transfected with MIPs produced more transgene expression data
that were within Q2 (i.e., high transgene expression and high total
cell counts; Figure 4D) compared to conditions where hMSCs were
transfected with conventional plasmids (Figure 4A), No F1 vectors
(Figure 4B), and MCs (Figure 4C). Analyzing EGFP-positive cell
counts as a negative binomial variable with total cell counts as an
offset term, indicated significant differences in EGFP-positive cell
counts between vectors at the same total cell count within promoter
(p < 0.01, Table S7), cationic carrier (p < 0.0001, Table S8), and donor
(p < 0.05, Table S9). Furthermore, MIP vectors resulted in signifi-
cantly higher EGFP-positive cell counts compared to all other vectors
tested in hMSCs (p < 0.001, Table S9), except for D4 hMSCs trans-
fected with plasmids (p < 0.07, Figure 4; Table S9).
Cationic carrier can affect hMSC transfection
In a similar manner used to compare promoters and bacterial ele-
ments, transgene expression data (i.e., number of EGFP-positive cells
Figure 1. Representative schematics of DNA vectors investigated in this study
DNA vector diagrams are not to scale. DNA vector diagramswere created with SnapGene. F1 Ori, F1 origin of replication; poly(A), polyadenylation signal; MC, minicircle; MIP,
mini-intronic plasmid.
www.moleculartherapy.org
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and total cell counts) were grouped for the two commercially available
cationic carriers (Figure 5). Conditions that made use of Turbofect, a
polymer-based cationic carrier, generally had transgene expression
data within Q3 (i.e., low transgene expression and low total cell
counts; Figure 5A), however, seven transfection conditions (condi-
tions in which hAMSCs were transfected with MIP CMV vectors)
of the 192 conditions/replicates were contained within Q2 (i.e.,
high transgene expression and high total cell counts; Figure 5A). Con-
ditions that made use of Lipofectamine 3000, a lipid-based cationic
carrier, had one condition within Q2 (D1 hAMSC transfected with
MIP CMV vectors; Figure 5B) but similar to Turbofect, the 64 condi-
tions that made use of Lipofectamine 3000 (Figure 2) generally pro-
duced transgene expression data within Q3 (Figure 5B). Furthermore,
analyzing EGFP-positive cell counts as a negative binomial variable,
with total cell counts as an offset term, indicated a significant differ-
ence in EGFP-positive cell counts between Lipofectamine 3000 and
Turbofect at the same total cell count within promoter (p < 0.05, Ta-
ble S10), vector (p < 0.01, Table S11), and donor (p < 0.01, Table S12);
however, due to our experimental design, it is difficult to conclude
with any statistical confidence that Lipofectamine 3000 results in
more EGFP-positive cells than Turbofect specifically between donors.
hMSC donor and tissue source can affect transfection
In a similar manner used to analyze promoters, bacterial elements,
and cationic carriers, transgene expression data (i.e., number of
EGFP-positive cell counts and total cell counts) for each hMSC donor
and tissue source were grouped (Table S1; Figure 6). Transfection of
hAMSCs generally resulted in transgene expression data within Q3
and Q4 (i.e., low transgene expression and varying total cell counts;
Figure 6A) while transfection of hBMSCs resulted in all but one con-
dition within Q3 (D4 hBMSCs transfected with No F1 CMV vector;
Figure 6B). We further separated the transgene expression data by
hMSC donor within each scatterplot in order to investigate transfec-
tion as a function of donor variability. For the two donors of hAMSCs,
D1 (orange symbols) had transfection conditions with fewer EGFP-
positive cells but higher total cell counts when compared to transfec-
tion conditions for D2 (Figure 6A; yellow symbols). However, there
was little difference in transgene expression data between the two do-
nors of hBMSCs (Figure 6B). Analyzing EGFP-positive cell counts as
a negative binomial variable, with total cell counts as an offset term,
indicated a significant difference in EGFP-positive cell counts be-
tween donors within promoter (p < 0.05, Table S13), vector (p <
0.05, Table S14), and cationic carrier (p < 0.05, Table S15); however,
due to our experimental design in which we blocked by donor, further
interpretation of statistical analysis on donor effects is not
appropriate.
DISCUSSION
hMSCs are primary cells isolated from a variety of tissue with high
clinical relevance,1,2 which could be enhanced through genetic modi-
fication. However, gene delivery, particularly through nonviral routes,
is inefficient.8,12–16,24We have previously reported enhanced nonviral
gene delivery to hMSCs by priming with pharmacologic agents,16 spe-
cifically with the glucocorticoid dexamethasone;13–15 however, work
remains to improve nonviral gene delivery to hMSCs, in particular
through evaluation of key variables of the nonviral gene delivery sys-
tem. This work systematically compares the key variables of nonviral
gene delivery systems (e.g., DNA vector type, DNA vector bacterial
elements, promoter, cationic carrier, and donor and tissue source)
and the effects of these variables on transfection outcomes. The trans-
fection outcomes varied widely for all 64 conditions tested (Tables 1;
Table S1; Figure 2), therefore, deliberate grouping of variables was
conducted in order to study the effects of each variable on hMSC
transfection.
In order to investigate the effects of DNA vector modification on
hMSC transfection, we first aggregated imaging transfection data
(i.e., number of EGFP-positive cells and total cell counts) for all con-
ditions tested and analyzed a single variable at a time. The first vari-
able that we investigated was promoter used to drive expression of the
transgene. The two promoters tested in this work (i.e., CMV and
EF1a) are widely used promoters for gene delivery shown to produce
high levels of transfection in numerous cell types.25,27 Even so, the
CMV promoter has shown significantly increased transfection levels
compared to the EF1a promoter, especially in hMSCs.14 Consistent
with other published work, in this work, the CMVpromoter did result
in significantly increased EGFP-positive cell counts compared to the
EF1a promoter when only the effects of the promoter were analyzed
(Figure 3; Table S4–S6). This significant increase in transfection by
the CMV promoter compared to the EF1a promoter may be from
increased transcription of the transgene, as Antonova and colleagues
have shown that the CMV promoter produces more transgenic
mRNA transcripts compared to other promoters in mouse and pri-
mary human fibroblasts.28 However, in this current report there
was no significant increase in transgenic mRNA transcripts in
hAMSCs from the CMV promoter compared to the EF1a promoter
for any of the conditions tested at either 12 or 24 h after delivery of
the transgene (Figure S3). While not significant, we did observe slight
increases in transgenic mRNA transcripts in hAMSCs transfected
with CMV DNA vectors compared to hAMSCs transfected with the
same DNA vector with the EF1a promoter. However, these increases
in transgenic mRNA transcripts likely do not contribute to the








vector for 1 mg/mL stocks
CMV 6.3 1 0
EF1a 6.9 1 0
CMV No F1 5.9 0.94 0.06
EF1a No F1 6.5 0.94 0.06
MC CMV 3.3 0.52 0.48
MC EF1a 3.9 0.57 0.43
MIP CMV 4.7 0.75 0.25
MIP EF1a 5.4 0.78 0.22
Kbp, kilobase pairs
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significant increases in transfection efficiency and transgenic lucif-
erase activity that we observed, and others have reported,14 from
the CMV promoter compared to the EF1a promoter. While this cur-
rent study confirms that the CMV promoter produces more transfec-
tion than the EF1a promoter in hMSCs frommultiple donors and tis-
sue sources, the mechanism of enhancement for the CMV promoter
needs further investigation.
Next, we investigated the effects of bacterial elements contained
within the DNA vector for their effect on transfection outcomes in
hMSCs. Conventional plasmids contain bacterial origins of replica-
tion and typically an antibiotic resistance gene for selection of
plasmid-harboring bacteria during plasmid propagation. These bac-
terial components, while necessary for DNA vector production,
have often been associated with an innate immune response through
recognition of pathogen associated molecular patterns (PAMPs;
e.g., unmethylated cytosine-phosphate-guanine [CpG]) by pattern
recognition receptors (PPRs),29,30 which may lead to transgene
silencing.31,32 Therefore, research into the development of highly effi-
cient nonviral gene delivery systems has focused on removing bacte-
rial elements from nonviral vectors.8,29 While the experiments in this
present work were not designed to study transgene silencing (i.e.,
transfection was assayed at a single time point following addition of
DNA vectors), we did observe slight increases in transgenic luciferase
activity when the F1 origin of replication (i.e., bacterial element) was
removed from conventional plasmids, compared to conventional
plasmids (Figures 2B and 2D). The F1 origin of replication is used
in conventional plasmids to replicate and package single-stranded
DNA into phages;33 however, the F1 origin of replication is not neces-
sary for conventional plasmid production or expression in mamma-
lian cells. Furthermore, Johnson and colleagues26 observed significant
increases in bactofection (i.e., delivery of genetic cargo to mammalian
cells using bacteria) of human breast cancer cells when the bacteria
were harboring plasmids with no F1 origin of replication, presumably
by rescuing DNA-induced stress. Therefore, removal of nonessential
bacterial elements within DNA vectors may increase transfection in
various cell types, particularly in hMSCs.
While removal of all bacterial elements is improbable for conven-
tional plasmid production, Chen and colleagues34 developed a
DNA vector devoid of all bacterial elements, termed MCs, and
showed increased transgene expression in vivo compared to conven-
tional plasmids. MCs are devoid of all bacterial elements, while also
having the ability to be propagated in engineered bacteria, through
excision and recombination of the expression cassette from a parental
plasmid, leaving a DNA vector that contains a promoter, transgene,
and a terminator sequence.34 MCs have since been shown to enhance
transfection in hMSCs,7,25,35–37 as well as stem cells from other spe-
cies,38,39 compared to conventional plasmids; however, in this current
study, MCs produced the lowest transfection efficiencies and trans-
gene expression observed, regardless of cationic carrier, promoter,
donor, or hMSC tissue source (Figures 2, 3, 4, 5, and 6). The large
Figure 2. Transfection efficiency and production of transgene for all 64 conditions tested
(A) Violin plots of transfection efficiency for the 32 transfection conditions where Turbofect was used as the cationic carrier. (B) Violin plots of transgenic luciferase activity
normalized to total protein amounts for the 32 transfection conditions where Turbofect was used as the cationic carrier. (C) Violin plots of transfection efficiency for the 32
transfection conditions where Lipofectamine 3000 was used as the cationic carrier. (D) Violin plots of transgenic luciferase activity normalized to total protein amounts for the
32 conditions that Lipofectamine 3000 was used as the cationic carrier. Parameters are identified within the legend provided.
www.moleculartherapy.org
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discrepancy in transfection outcomes fromMCs observed in this cur-
rent study compared to other published studies may be from our
normalization of both moles of expression cassette (i.e., transgene)
and mass of DNA delivered (Table 2). For example, Mun and col-
leagues25 observed higher transfection efficiencies in hAMSCs and
hBMSCs using an EGFP expressing MC compared to an EGFP ex-
pressing plasmid when equal moles of expression cassette were deliv-
ered (i.e., higher mass of plasmid delivered than mass of MC). Alter-
natively, Boura and colleagues36 delivered equal mass of MCs (i.e.,
higher molarity of expression cassette for MCs compared to plasmid)
encoding for human leukocyte antigen-G1 (HLA-G1) to hBMSCs as
plasmids carrying HLA-G1 and observed significantly higher expres-
sion of HLA-G1 from MCs in hBMSCs compared to a plasmid with
the same promoter. Furthermore, Zimmermann and colleagues7
showed significantly more alkaline phosphatase (ALP) activity in
hBMSCs transfected with a bone morphogenetic protein 2 (BMP2)
encoding MC compared to a conventional plasmid encoding
BMP2, when equal mass of DNA was delivered (i.e., higher molarity
of expression cassette for MCs compared to plasmid); however, when
equal moles of expression cassette was delivered (i.e., higher mass of
plasmid delivered thanmass ofMCs), BMP2 encodingMCs produced
the same levels of ALP activity compared to BMP2 encoding plas-
mids. Indeed, we have observed increased transfection in hMSCs
with MCs compared to conventional plasmids when equal mass of
DNA vector was delivered but not equal moles of expression cassette
(T.K., unpublished data); however, delivering equal mass of vectors
with drastically different sizes is not a fair comparison as there will
always be higher concentrations of expression cassette for the smaller
vector (i.e., MC) than the larger vector (i.e., conventional plasmid),
potentially increasing the probability of successful transfection for
the smaller vector. Furthermore, delivering equal moles of expression
cassette is also not a fair comparison for DNA vectors with drastically
different sizes as the larger vector (i.e., conventional plasmid) will al-
ways have more mass of DNA than the smaller vector (i.e., MC),
potentially leading to more toxicity than the smaller vector, as Zim-
mermann and colleagues observed a significant decrease in viability
for conventional plasmids compared to MCs when equal moles of
transgene were delivered (i.e., higher mass of conventional plasmid).7
Therefore, we recommend that both moles of transgene and mass of
DNA delivered need to be normalized in order to robustly compare
DNA vectors with drastically different sizes. However, whether the
transfection by MC observed in other studies is due to the lack of bac-
terial elements or the vectors’ small size compared to conventional
plasmids, or whether the lack of transfection observed in this work
is due to lower copy numbers of the expression cassette for a given
mass of DNA delivered, needs further investigation.
Another DNA vector with reduced bacterial components, which re-
tains the ability to propagate in conventional bacteria, was developed
by the Kay Lab.19 These vectors, termedMIPs, contain all bacterial el-
ements necessary for vector propagation in an engineered intron
within the expression cassette.19 The idea to incorporate bacterial el-
ements within an engineered intron in the expression cassette
stemmed from observations of in vivo transgene silencing when the
extragenic space between the 50 and 30 ends of the expression cassette
was greater than 1 kb.31 The authors hypothesized that shortening the
extragenic space between the 50 and 30 ends of the expression cassette
could allow for more efficient gene looping, a mechanism in which the
promoter and terminator regions are juxtaposed in a transcription-
dependent manner,40 thereby promoting efficient transcriptional
elongation and recycling of RNA polymerase II from the terminator
to the promoter. Their hypothesis that shortening the extragenic
Figure 3. Transgene expression data as a function of
DNA vector promoter in human mesenchymal stem
cells (hMSCs)
(A) Scatterplot showing aggregated EGFP-positive cells
and total cell counts for all transfection conditions (TableS1;
Table 1) with the CMV promoter in all donors of hMSCs. (B)
Scatterplot showing aggregated EGFP-positive cells and
total cell counts for all transfection conditions (Table S1;
Table 1) with the EF1a promoter in all donors of hMSCs.
Quadrant 1 (Q1) represents high transgene expression but
low total cell counts, which could be attributed to either
transfection-induced toxicity and/or a reduction in prolif-
eration. Q2 represents high transgene expressionwith high
total cell counts, which could be attributed to eitherminimal
transfection-induced toxicity and/or minimal reduction in
proliferation. Q3 represents both low transgene expression
and low total cell counts. Lastly, Q4 represents low trans-
gene expression but high total cell counts. It should be
noted that these quadrants were partitioned using the
highest number of EGFP-positive cells and total cell counts
that were observed in this current study; therefore, these
quadrant boundaries should not be used to evaluate con-
ditions and data from other studies. Lines represent
the Poisson regression line that best fits the data. Param-
eters are identified within the legend provided.
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space would allow for more efficient gene looping was never verified,
but Lu and colleagues19 did observe enhanced transfection with MIPs
in mice and in human cells compared to plasmids and MCs. Indeed,
MIPs produced the highest transfection efficiencies and transgene
expression in this current study in both donors of hAMSCs compared
to all other vectors, regardless of cationic carrier or promoter (Figures
2, 3, 4, 5, and 6). Additionally, we observed significantly more trans-
genic mRNA transcripts from hAMSCs transfected with MIP EF1a
compared to hAMSCs transfected with either CMV or EF1a plasmids
at 24 h (Figure S3); however, similar results were not observed for
hAMSCs transfected with MIP CMV (Figure S3). The high transfec-
tion levels from MIPs observed in this current study, as well as other
published work,19,22,41 may be from the inclusion of an intron within
the expression cassette, as others have shown increased transgene
expression42 or mRNA transcripts43 when introns were inserted
into the expression cassette. Introns have long been thought of as su-
perfluous genetic material and were traditionally removed from
transgenes prior to ligating into a DNA vector; however, introns
have been shown to play vital roles in transgene expression, such as
transcription,43 polyadenylation,44 and mRNA export and decay,45
as well as translational efficiency.46 Given the transfection levels
observed in this current study by MIPs, as well as the transgenic
mRNA transcript levels at 12 and 24 h after transfection, it is plausible
that the engineered intron within the expression cassette of MIPs
might be promoting transcription42,43 or limiting mRNA decay
(i.e., significantly higher transgenic mRNA transcripts for MIPs in
Figure 4. Transgene expression data as a function of DNA vector bacterial elements in hMSCs
(A) Scatterplot showing aggregated EGFP-positive cells and total cell counts for all plasmid vector conditions in all donors of hMSCs. (B) Scatterplot showing aggregated
EGFP-positive cells and total cell counts for all plasmid conditions with the F1 origin of replication removed (No F1) in all donors of hMSCs. (C) Scatterplot showing aggregated
EGFP-positive cells and total cell counts for all MC vector conditions in all donors of hMSCs. (D) Scatterplot showing aggregated EGFP-positive cells and total cell counts for
all MIP conditions in all donors of hMSCs. Q1 represents high transgene expression but low total cell counts, which could be attributed to either transfection-induced toxicity
and/or a reduction in proliferation. Q2 represents high transgene expression with high total cell counts, which could be attributed to either minimal transfection-induced
toxicity and/or minimal reduction in proliferation. Q3 represents both low transgene expression and low total cell counts. Lastly, Q4 represents low transgene expression but
high total cell counts. It should be noted that these quadrants were partitioned using the highest number of EGFP-positive cells and total cell counts that were observed in this
current study, therefore, these quadrant boundaries should not be used to evaluate conditions and data from other studies. Lines represent the Poisson regression line that
best fits the data. Parameters are identified within the legend provided.
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D1 hAMSCs compared to both the CMV and EF1a conventional
plasmid, regardless of promoter used; Figures S3B and S3D) or are
enhancing translation in hAMSCs42 (i.e., higher transfection effi-
ciency and transgene expression by MIPs compared to other vectors
tested regardless of promoter or cationic carrier in hAMSCs; Figure 4).
However, in hBMSCs, increases in transfection efficiency and trans-
gene expression byMIPs were only observed when the EF1a promoter
was used (Figure 2), possibly due to the incorporation of a second
intron within the EF1a promoter42 or differences in intron processing
by the cells.47 However, studies comparing transcription and transla-
tion efficiency differences from either gene looping or incorporation
of one or more introns are needed to fully elucidate the transfection
enhancements observed by MIPs in hMSCs.
In addition to the above transfection parameters, research has shown
that polymer- and lipid-mediated nonviral gene delivery efficacy can
be dependent on cationic carrier formulation; however, limited
research has been conducted on how polymer- and lipid-mediated
transfection can be affected by different DNA vectors,48 in particular
within the context of hMSCs frommultiple donors and tissue sources.
Here, two commercially available transfection reagents were used,
which represent both lipid- and polymer-based systems: Lipofect-
amine 3000 and Turbofect, respectively. These commercially avail-
able transfection reagents were chosen as they are readily available,
widely used, and have shown moderate levels of transfection in
hMSCs14–16,24 (T.K., A.H., and L.S., unpublished data). This study
did not include other modes of delivery (e.g., electroporation) given
the complexities involved in comparing carrier-based systems to
physical methods, but future studies should investigate other delivery
strategies in the context of the parameters investigated here.
In this current study, there were differences in transfection effi-
ciencies and transgene production between the two cationic carriers
(Figure 2) and Poisson regressions of aggregated transgene expression
data for each cationic carrier showed slight differences in overall
transfection trends (Figure 5). Indeed, others have shown differences
in transfection outcomes in hMSCs between polymer- and lipid-
based systems, with either polymer-49 or lipid-based23 systems pro-
ducing the highest transgene expression. Furthermore, we observed
significantly different total cell ratios for tested cationic carriers (Tur-
bofect total cell count divided by the total cell count for the same con-
dition complexed with Lipofectamine 3000, which is an indirect mea-
sure of toxicity and/or proliferative effects of Turbofect relative to
Lipofectamine 3000) between hAMSCs and hBMSCs (Figure S4),
highlighting another transfection parameter that needs to be carefully
considered in a hMSC nonviral gene delivery system. Indeed, our pre-
vious studies on hMSC transfection with lipid-based cationic carriers
extensively characterized both cellular proliferation (through meta-
bolic studies)13 and transfection-induced toxicity,15 and showed
that rescuing transfection-induced metabolic shut down and toxicity
could enhance transfection efficiency and transgene production.13,15.
Taken together, cationic carrier selection does not have a large effect
on overall transfection outcomes; however, transfection and total cell
counts, which are an indirect measure of cytotoxicity and/or prolifer-
ative nature, can be optimized if the cationic carrier is selected based
on hMSC tissue source.
Finally, hMSCs can be harvested frommultiple tissues in the adult hu-
man body50,51 and, due to their immunomodulatory effects,5,52 have
the potential for allogenic use,53 making both donor and tissue source
pertinent variables in this study. hMSCs have been shown to have
Figure 5. Transgene expression data as a function of
cationic carrier in hMSCs
(A) Scatterplot showing aggregated EGFP-positive cells
and total cell counts for all transfection conditions where
the polymer transfection reagent Turbofect was used as
the cationic carrier in all donors of hMSCs. (B) Scatterplot
showing aggregated EGFP-positive cells and total cell
counts for all vectors where the lipid transfection reagent
Lipofectamine 3000 was used as the cationic carrier in all
donors of hMSCs. Q1 represents high transgene expres-
sion but low total cell counts, which could be attributed to
either transfection-induced toxicity and/or a reduction in
proliferation. Q2 represents high transgene expression
with high total cell counts, which could be attributed to
eitherminimal transfection-induced toxicity and/orminimal
reduction in proliferation. Q3 represents both low trans-
gene expression and low total cell counts. Lastly, Q4 rep-
resents low transgeneexpressionbut high total cell counts.
It should be noted that these quadrants were partitioned
using the highest number of EGFP-positive cells and total
cell counts that were observed in this current study,
therefore, these quadrant boundaries should not be used
to evaluate conditions and data from other studies. Lines
represent thePoisson regression line that best fits the data.
Parameters are identified within the legend provided.
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large variability in gene expression, proliferative capacity, differentia-
tion capacity, and transfection efficacy between the donor and tissue
source from which they were obtained;13–15,24,50,54 however, these pa-
rameters have not been studied in depth as they pertain to DNA vec-
tor modifications and transfection outcomes.13,14 Here, the data show
discrepancies in trends between transfection outcomes for each con-
dition between the different donors and tissue sources (Figure 2),
which may be partly attributed to the different proliferation rates be-
tween hMSCs from different donors and tissue source.50 Generally,
hAMSCs have higher proliferation rates compared to hBMSCs,50
which may increase nuclear internalization of DNA vectors due to
the increased nuclear breakdown, thereby giving hAMSCs a higher
probability of successful transfection compared to hBMSCs. The
slower proliferating hBMSCs may have lower probabilities of success-
ful transfection due to less nuclear breakdown but have a higher DNA
vector-to-cell ratio due to their lower cell numbers compared to
hAMSCs (Figure 6), possibly causing an increase in transfection-
induced toxicity (Figure S4) due to the higher DNA vector dose, as
others have observed.55 However, further studies are needed in order
to elucidate the discrepancies in transfection efficiency and transgene
expression observed in this study between different conditions on a
hMSC donor and tissue source basis.
Conclusions
This work systematically investigated the effects of DNA vector mod-
ifications (i.e., promoter, bacterial element quantities, and positions
within the vector) on transfection in hMSCs from different donors
and tissue sources using two commercially available cationic carriers.
Analyzing each variable separately, we observed differences in trans-
fection outcomes based on promoter selection, DNA vector, and
cationic carrier, as well as donor and tissue source. Notably, we
observed the highest levels of transgene expression when MIPs, com-
plexed with Lipofectamine 3000, were delivered to hAMSCs and
transgene production was under control of the CMV promoter.
Furthermore, the presented data provide valuable insight into the
importance of hMSC donor and tissue source variability as they
pertain to DNA vector modifications for nonviral gene delivery.
This work demonstrates that transfection parameters may need to
be tuned in an application- and patient-specific manner in order to
achieve efficient transfection in hMSCs for clinical therapies.
MATERIALS AND METHODS
Cell culture
Cryopreserved hMSCs from four human donors and two tissue sour-
ces were purchased at passage two from Lonza (Lonza, Walkersville,
MD, USA) and were used at passage six (see Table S1 for donor infor-
mation). Adipose-derived hMSCs (hAMSCs) were positive for CD13,
CD29, CD44, CD73, CD90, CD105, CD166, and negative for CD14,
CD31, and CD45 cell surface markers. Bone-marrow-derived hMSCs
(hBMSCs) were positive for CD29, CD44, CD105, and CD166 and
negative for CD14, CD34, and CD45 cell surface markers. hMSCs
were passaged and cultured in hMSC media, consisting of minimum
essential medium alpha (MEM Alpha; GIBCO, Grand Island, NY,
USA) supplemented with 10% heat-inactivated fetal bovine serum
(FBS; GIBCO), 6 mM L-Glutamine (GIBCO), and 1% penicillin-
streptomycin (Pen-Strep; 10,000 U/mL; GIBCO), and incubated at
37C with 5% CO2 until confluent. At confluence, hMSC media
was removed and cells were washed with 1 phosphate-buffered
saline (PBS) prior to the addition of 0.25% trypsin-ethylenediamine
tetraacetic acid (EDTA; GIBCO) for cellular dissociation. After disso-
ciation, an equal volume of hMSC media was added and total cellular
suspension was removed for subsequent cell pelleting via
Figure 6. Transgene expression data as a function
of hMSC tissue source and donor
(A) Scatterplot showing aggregated EGFP-positive cells
and total cell counts for all transfection conditions in both
donors of adiposed-derived hMSCs (hAMSCs). (B) Scat-
terplot showing aggregated EGFP-positive cells and total
cell counts for all transfection conditions in both donors of
bone-marrow-derived hMSCs (hBMSCs). Q1 represents
high transgene expression but low total cell counts, which
could be attributed to either transfection-induced toxicity
and/or a reduction in proliferation. Q2 represents high
transgene expression with high total cell counts, which
could be attributed to either minimal transfection-induced
toxicity and/or minimal reduction in proliferation. Q3 rep-
resents both low transgene expression and low total cell
counts. Lastly, Q4 represents low transgene expression
but high total cell counts. It should be noted that these
quadrants were partitioned using the highest number
of EGFP-positive cells and total cell counts that were
observed in this current study; therefore, these quadrant
boundaries should not be used to evaluate conditions and
data from other studies. Lines represent the Poisson
regression line that best fits the data. Parameters are
identified within the legend provided.
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centrifugation to remove trypsin-EDTA. Cells were resuspended in
warm hMSCmedia and counted via trypan blue exclusion using a he-
mocytometer prior to diluting in hMSC media for seeding, as
described next.
For seeding of hAMSCs, cells were dissociated and counted, as
described above, and 100 mL of 4.5  104 cells/mL cell suspension
(4,500 cells/well; D1 and D2) was added to each well of clear bottom,
black walled, 96-well plates (Corning Life Sciences, Corning, NY,
USA). Immediately following seeding, plates were incubated at
37C and 5% CO2 and allowed to culture for 24 h. For seeding of
hBMSCs, cells were dissociated and counted, as described above,
and 100 mL of 4  104 cells/mL cell suspension (4,000 cells/well;
D3 & D4) was added to each well of clear bottom, black walled, 96-
well plates (Corning Life Sciences). Immediately following seeding,
plates were incubated at 37C and 5% CO2 and allowed to culture
for 48 h. The different seeding densities and culture times for
hAMSCs (4.5  104 cells/mL, 24 h) and hBMSCs (4  104 cells/
mL, 48 hours) were selected so all experimental conditions were at
80% confluence before transfecting, as described below.
DNA vectors
All DNA vectors used in this screen encode for a fusion protein of
EGFP and firefly luciferase (EGFPLuc, Figure 1 and Table 1).
pTubb3-MC was a gift from Juan Belmonte (Addgene plasmid
#87112; http://n2t.net/addgene:87112; RRID: Addgene_87112)56
and was used to clone minicircle (MC) vectors MC.EGFPLuc-
CMV, MC.EGFPLuc-EF1a, and MC.Expressionless (Genscript, Pis-
cataway, NJ, USA). MIP 247 CoMIP 4in1 with shRNA p53 was a
gift from Mark Kay and Joseph Wu (Addgene plasmid #63726;
http://n2t.net/addgene:63726; RRID: Addgene_63726)22 and was
used to clone MIP vectors MIP.EGFPLuc-CMV, MIP.EGFPLuc-
EF1a, and MIP.Expressionless (Genscript). The F1 origin of replica-
tion was removed from EGFPLuc-CMV (Clontech, Mountain
View, CA, USA) and pEGFPLuc-EF1a (Genscript) in order to clone
pEGFPLuc-CMV No F1 and pEGFPLuc-EF1a No F1, respectively
(Genscript). MC vectors (MC.EGFPLuc-CMV, MC.EGFPLuc-EF1a,
and MC.Expressionless) were propagated in the bacterial strain
ZYCY10P3S2T (System Biosciences, Palo Alto, CA) under kana-
mycin selection following a published protocol,57 with minor
changes. Briefly, 100 mL of Terrific Broth (TB; Invitrogen) was inoc-
ulated with bacterial strain ZYCY10P3S2T containing MC vectors
and cultured overnight at 37C with shaking at 250 RPM. The
overnight culture was then mixed with minicircle induction mix
comprising 100 mL of Luria-Bertani broth (LB; Becton Dickinson,
Franklin Lakes, NJ, USA), 4 mL of 1N NaOH, and 100 mL of 20%
L-arabinose, and cultured for 5 h at 32C with shaking at 250
RPM. All MIP vectors (MIP.EGFPLuc-CMV, MIP.EGFPLuc-EF1a,
and MIP.Expressionless) were propagated in RNA-OUT competent
cells (Nature Technologies, Lincoln, NE, USA)58 using 6% sucrose se-
lection media. All plasmids (pEGFPLuc-CMV, pEGFPLuc-CMV No
F1, pEGPFLuc-EF1a, and pEGFPLuc-EF1a) were propagated in
DH5a e. coli. (Invitrogen, Carlsbad, CA, USA) under kanamycin se-
lection. All DNA vectors were isolated and purified using a Purelink
High Purity Endotoxin free plasmid purification kit (Invitrogen).
DNA quality and yield were measured using a Nanodrop (Thermo
Fisher Scientific) and all DNA vectors were resuspended in Tris
EDTA (TE) buffer at a concentration of 1 mg/mL.
In order to compare DNA vectors, an equal amount of transgene (i.e.,
molarity of expression cassette) and DNA mass was delivered to
hMSCs for each DNA vector. Molarity of expression cassette for
each DNA vector was normalized by dividing the size of each DNA
vector (in kilobase pairs) by the size of the largest DNA vector (in
kilobase pairs) for each promoter. DNA mass was then equalized
by adding the remaining fraction of corresponding expressionless
vector to make all DNA vector stocks be 1 mg/mL (Table 2).
hMSC transfection
24 h after seeding of hAMSCs, or 48 h after seeding of hBMSCs, as
described above, all DNA vectors were complexed with either Lipo-
fectamine 3000 (Invitrogen) at a DNA:lipid ratio of 1:2 in serum
free Opti-MEMmedia (Invitrogen) following themanufacturer’s pro-
tocol or complexed with Turbofect (Thermo Fisher Scientific) at a
DNA:polymer ratio of 1:4 in serum free Opti-MEM media following
manufacturer’s protocol. After complex formation, 0.07 mg of Lipo-
fectamine 3000 complexed DNA vector in 6.7 mL of Opti-MEM or
0.07 mg of Turbofect complexed DNA vector in 11.1 mL of Opt-
MEM was delivered to each well, and plates were briefly centrifuged
to ensure mixing of complexes with the hMSC media. Media were
removed immediately after centrifugation and replaced with fresh,
warmed, hMSC media lacking complexes. Following complex deliv-
ery, hMSCs were placed into incubators at 37C and 5% CO2 and al-
lowed to culture for 48 h.
Cell staining and high content imaging for transfection
efficiency assessment
48 h after delivery of complexes, cells were stained with Hoechst
33342 (Sigma-Aldrich, St. Louis, MO, USA) to enable nuclei counts
for assessment of EGFP transfection efficiencies. After removing cul-
ture media from the cells, 50 mL of staining solution (1 mg/mL of
Hoechst in hMSC media) was added to each well and incubated for
25 min at 37C and 5% CO2. After incubation, staining solution
was removed, and cells were rinsed with 20 mL of 1 PBS on a
multi-purpose rotator for 5 min, after which the rinse was removed
and 100 mL of 1 PBS was added to each well for subsequent imaging.
Images of each well were acquired with a Cytation 1 Cell Imaging Sys-
tem (Biotek, Winooski, VT, USA), equipped with a laser autofocus
cube and GFP (EGFP transgene production) and DAPI (nuclei count
via Hoechst) filter cubes paired with 465 nm and 365 nm LED cubes,
respectively. Two images, spaced 150 mm apart vertically, were taken
of each well in each fluorescent channel, in addition to phase contrast
images, using a 4 objective. Consistent fluorescence excitation LED
intensity and camera exposure settings were used to allow for com-
parison of image intensities between wells in the same plate. After im-
aging, cells were washed with PBS and lysed with 150 mL per well of
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1 reporter lysis buffer (Promega, Madison, WI, USA) by incubating
at room temp for 10 min prior to storage at 80C.
Assessment of transfection efficiency and transgene expression
levels
Gen5 software (Biotek) was used for image preprocessing and decon-
volution (to subtract background fluorescence from captured digital
images), as well as object analysis (e.g., EGFP-positive cells and cell
nuclei) in order to calculate transfection efficiencies. Object analysis
identified objects of interest in all channels by their fluorescence in-
tensity and size. DAPI and GFP intensity thresholds were set at
5,000 and 1,000 relative fluorescent units (RFUs), respectively, and
minimum and maximum object size were set at 12 and 50 (DAPI)
and 12 and 150 (GFP).
Transfection efficiency was calculated by dividing the number of
EGFP objects (cells producing transgene) by the number of DAPI ob-
jects (cell nuclei) in the same well. Transgenic luciferase activity levels
were quantified by measuring luciferase luminescence in RLUs with a
Luciferase Assay kit (Promega) and a luminometer (Turner Designs,
Sunnyvale, CA, USA). RLUs were normalized to total protein amount
determined with a Pierce bicinchoninic acid (BCA) colorimetric assay
(Pierce, Rockford, IL, USA) using an Epoch plate reader (Biotek) to
measure absorbance at 562 nm.
Quantification of transgenic mRNA
To quantify relative mRNA transcript copy numbers of the EGFPLuc
transgene from each DNA vector, we seeded D6 hAMSCs at 4.5 104
cells/mL (4,500 cells/well), as described above, and cultured at 37C
and 5% CO2. 24 h after seeding, D1 hAMSCs were transfected with
DNA vectors complexed with Turbofect transfection reagent, as
described above. 12 and 24 h following transfection, mRNA was iso-
lated for each condition using SingleShot Cell Lysis Kit (Bio-Rad,
Hercules, CA, USA) following the manufacturer’s protocol. Isolated
mRNA was then reverse transcribed using iScript cDNA Synthesis
Kit (Bio-Rad) following the manufacturer’s protocol. qRT-PCR was
performed on a QuantStudio 6 Flex Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) with Power SYBR Green Master
Mix (Thermo Fisher Scientific) and relative expression was calculated
by the DDCt method normalizing to the endogenous control
RPL13A. See Table S2 for primer sequences (Integrated DNA Tech-
nologies, Coralville, IA, USA).
Data analysis and statistics
In this study, two promoters in eight DNA vectors complexed with
two commercially available transfection reagents were investigated
in four donors of hMSCs from two tissue sources (64 conditions).
Our experimental design for this study was a split-plot design with
the whole plot factor being the cationic carrier and the split plot factor
being vector  promoter after blocking by donor. All data are re-
ported as the mean of triplicate values for each condition on duplicate
days (n = 6), except where noted. In order to compare each variable
tested, the EGFP cell counts and total cell counts for all 64 conditions
tested (Figure 2) were aggregated for that particular variable and pre-
sented in scatterplots (Figures 3, 4, 5, and 6) divided into four quad-
rants. Q1 represents high transgene expression but low total cell
counts (which could be attributed to either transfection-induced
toxicity and/or a reduction in proliferation). Q2 represents high
transgene expression with high total cell counts (which could be
attributed to either minimal transfection-induced toxicity and/or
minimal reduction in proliferation). Q3 represents both low trans-
gene expression and low total cell counts. Lastly, Q4 represents low
transgene expression but high total cell counts. It should be noted
that these quadrants were partitioned using the highest number of
EGFP-positive cells and total cell counts that were observed in this
current study; therefore, these quadrant boundaries should not be
used to evaluate conditions and data from other studies. Poisson re-
gressions, with the line forced through the origin, were performed for
each scatterplot (i.e., variable) in order to visually identify differences
in EGFP cell counts versus total cell counts for each variable tested.
EGFP-positive cell count data represented in the scatterplots were
analyzed as a negative binomial variable with the total cell counts
as an offset term. Kenward-Roger adjustment was used on the degrees
of freedom to account for the multiple error levels in the analysis.
Transfection efficiency and transgenic luciferase activity fold changes
were calculated for all pairwise comparisons for each donor by
dividing the six transgene expression values for each column condi-
tion by the average (n = 6 for each condition) of the row condition
(Figures S1 and S2). Relative transgenic mRNA transcript fold-
changes were analyzed using an ANOVA with Dunnett’s post hoc
test. Statistical significance was accepted for p values less than 0.05.
Statistics were evaluated using Prism GraphPad software (GraphPad
Software, La Jolla, CA, USA) and SAS/STAT 14.2 software, version
9.4 of the SAS system for Windows. Copyright 2016 SAS Institute
SAS and all other SAS Institute product or service names are regis-
tered trademarks or trademarks of SAS Institute (SAS Institute,
Cary, NC, USA).
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Table S1: hMSC Donor Information 
Donor ID Tissue Source Age Sex Ethnicity/Race 
D1 Adipose 22 M Black 
D2 Adipose 42 F Black 
D3 Bone Marrow 22 M Not provided 
D4 Bone Marrow 31 M Black 
 
Table S2: Sequences of Primers Used in qRT-PCR 
EGFP Forward 5’-ACGTAAACGGCCACAAGTTC-3’ 
EGFP Reverse 5’-AAGTCGTGCTGCTTCATGTG-3’ 
RPL-13A Forward 5’-CCTGGAGGAGAAGAGGAAAGAGA-3’ 
RPL-13A Reverse 5’-TTGAGGACCTCTGTGTATTTGTCAA-3’ 
 
 
Table S4: Pairwise Comparisons Between Promoters for Each Vector 
Vector Promoter _Promoter Estimate SE DF t Value Pr > |t| Adj P 
Plasmid CMV EF1a 1.8122 0.09838 353 18.42 <.0001 <.0001 
No F1 CMV EF1a 1.9739 0.09191 316 21.48 <.0001 <.0001 
MC CMV EF1a 1.8122 0.09838 353 18.42 <.0001 <.0001 
MIP CMV EF1a 1.1076 0.08760 262.6 12.64 <.0001 <.0001 
EGFP positive cell counts for each promoter were analyzed as a negative binomial with total cell count 
as an offset term.  Promoter effects within each vector were compared using least square means with use 
of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the 
estimated responses for each promoter; SE, standard error; DF, degrees of freedom; t value, t-test 
statistic; Pr > |t|, p-value associated with the t statistic; Adj P, adjusted p-value.  Significance was 
accepted at p<0.05.   
 
  
Table S3: Type III Tests of Fixed Effects 
Effect DF Den DF F Value Pr > F 
Cationic Carrier 1 4.134 15.05 0.0168 
Donor 3 4.001 10.12 0.0244 
Promoter 1 330.7 1455.64 <.0001 
Vector 3 326 186.99 <.0001 
Cationic Carrier*Donor 3 4.047 12.85 0.0156 
Cationic Carrier*Promoter 1 321.4 85.87 <.0001 
Cationic Carrier*Vector 3 310.9 8.16 <.0001 
Donor*Promoter 3 321 18.07 <.0001 
Donor*Vector 9 310 13.37 <.0001 
Promoter*Vector 3 325.5 27.72 <.0001 
EGFP positive cell counts for each effect (variable) were analyzed as a negative binomial with total cell 
count as an offset term.  Kenward-Rogers adjustment was used on the degrees of freedom to account for 
the multiple error levels in our analysis.  DF, degrees of freedom; Den DF, degrees of freedom associated 
with model errors; F-Value, F-test statistic; Pr > F, p-value associated with the F statistic. Significance 
was accepted at p<0.05. 
Table S5: Pairwise Comparisons Between Promoters for Each Cationic Carrier 
Cationic Carrier Promoter _Promoter Estimate SE DF t Value Pr > |t| 
Turbofect CMV EF1a 2.2020 0.06665 345.7 33.04 <.0001 
Lipofectamine CMV EF1a 1.3440 0.06453 306.8 20.83 <.0001 
EGFP positive cell counts for each promoter were analyzed as a negative binomial with total cell count 
as an offset term.  Promoter effects within each cationic carrier were compared using least square means 
with use of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between 
the estimated responses for each promoter; SE, standard error; DF, degrees of freedom; t value, t-test 
statistic; Pr > |t|, p-value associated with the t statistic.  Significance was accepted at p<0.05. 
 
Table S6: Pairwise Comparisons Between Promoters for Each Donor 
Donor Promoter _Promoter Estimate SE DF t Value Pr > |t| Adj P 
D1 CMV EF1a 1.2843 0.09338 331.9 13.75 <.0001 <.0001 
D2 CMV EF1a 1.6203 0.09204 311.3 17.61 <.0001 <.0001 
D3 CMV EF1a 2.0922 0.09429 347.6 22.19 <.0001 <.0001 
D4 CMV EF1a 2.0951 0.09100 304.5 23.02 <.0001 <.0001 
EGFP positive cell counts for each promoter were analyzed as a negative binomial with total cell count 
as an offset term.  Promoter effects within each donor were compared using least square means with use 
of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the 
estimated responses for each promoter; SE, standard error; DF, degrees of freedom; t value, t-test 
statistic; Pr > |t|, p-value associated with the t statistic; Adj P, adjusted p-value.  Significance was 
accepted at p<0.05.   
 
Table S7: Pairwise Comparisons Between Vectors for Each Promoter 
Promoter Vector _Vector Estimate SE DF t Value Pr > |t| Adj P 
CMV MC MIP -1.1961 0.08807 268.2 -13.58 <.0001 <.0001 
CMV MC No F1 -0.8637 0.08838 272 -9.77 <.0001 <.0001 
CMV MC Plasmid -0.8924 0.08863 275 -10.07 <.0001 <.0001 
CMV MIP No F1 0.3324 0.08651 250.1 3.84 0.0002 0.0009 
CMV MIP Plasmid 0.3036 0.08677 253 3.50 0.0006 0.0031 
CMV No F1 Plasmid -0.02875 0.08708 256.7 -0.33 0.7415 0.9876 
EF1a MC MIP -1.9006 0.09797 353 -19.40 <.0001 <.0001 
EF1a MC No F1 -0.7020 0.1016 353 -6.91 <.0001 <.0001 
EF1a MC Plasmid -0.5063 0.1026 353 -4.93 <.0001 <.0001 
EF1a MIP No F1 1.1987 0.09291 329.2 12.90 <.0001 <.0001 
EF1a MIP Plasmid 1.3943 0.09413 347.9 14.81 <.0001 <.0001 
EF1a No F1 Plasmid 0.1956 0.09785 353 2.00 0.0463 0.1901 
EGFP positive cell counts for each vector were analyzed as a negative binomial with total cell count as 
an offset term.  Vector effects within each promoter were compared using least square means with use 
of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the 
estimated responses for each vector; SE, standard error; DF, degrees of freedom; t value, t-test statistic; 
Pr > |t|, p-value associated with the t statistic; Adj P, adjusted p-value.  Significance was accepted at 
p<0.05.  Red highlighted adjusted p-values indicate no significant difference at α=0.05 
  
Table S8: Pairwise Comparisons Between Vectors for Each Cationic Carrier 
Cationic Carrier Vector _Vector Estimate SE DF t Value Pr > |t| Adj P 
Turbofect MC MIP -1.5044 0.09400 336.9 -16.00 <.0001 <.0001 
Turbofect MC No F1 -0.5944 0.09662 353 -6.15 <.0001 <.0001 
Turbofect MC Plasmid -0.8299 0.09659 353 -8.59 <.0001 <.0001 
Turbofect MIP No F1 0.9100 0.09115 303 9.98 <.0001 <.0001 
Turbofect MIP Plasmid 0.6745 0.09114 303.4 7.40 <.0001 <.0001 
Turbofect No F1 Plasmid -0.2355 0.09386 336.1 -2.51 0.0126 0.0604 
Lipofectamine 3000 MC MIP -1.5923 0.09171 312.6 -17.36 <.0001 <.0001 
Lipofectamine 3000 MC No F1 -0.9712 0.09288 327.9 -10.46 <.0001 <.0001 
Lipofectamine 3000 MC Plasmid -0.5689 0.09420 345.3 -6.04 <.0001 <.0001 
Lipofectamine 3000 MIP No F1 0.6211 0.08815 268.8 7.05 <.0001 <.0001 
Lipofectamine 3000 MIP Plasmid 1.0235 0.08956 285.5 11.43 <.0001 <.0001 
Lipofectamine 3000 No F1 Plasmid 0.4023 0.09078 300.4 4.43 <.0001 <.0001 
EGFP positive cell counts for each vector were analyzed as a negative binomial with total cell count as 
an offset term.  Vector effects within each cationic carrier were compared using least square means with 
use of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the 
estimated responses for each vector; SE, standard error; DF, degrees of freedom; t value, t-test statistic; 
Pr > |t|, p-value associated with the t statistic; Adj P, adjusted p-value.  Significance was accepted at 
p<0.05.  Red highlighted adjusted p-values indicate no significant difference at α=0.05 
  
Table S9: Pairwise Comparisons Between Vectors for Each Donor 
Donor Vector _Vector Estimate SE DF t Value Pr > |t| Adj P 
D1 MC MIP -1.7418 0.1318 329.4 -13.22 <.0001 <.0001 
D1 MC No F1 -0.3901 0.1353 353 -2.88 0.0042 0.0216 
D1 MC Plasmid -0.2420 0.1367 353 -1.77 0.0777 0.2898 
D1 MIP No F1 1.3517 0.1267 283.9 10.67 <.0001 <.0001 
D1 MIP Plasmid 1.4998 0.1283 298.4 11.69 <.0001 <.0001 
D1 No F1 Plasmid 0.1481 0.1320 328.4 1.12 0.2624 0.6758 
D2 MC MIP -2.3004 0.1325 328.6 -17.37 <.0001 <.0001 
D2 MC No F1 -1.5455 0.1338 340.6 -11.55 <.0001 <.0001 
D2 MC Plasmid -1.2590 0.1355 353 -9.29 <.0001 <.0001 
D2 MIP No F1 0.7549 0.1242 264.7 6.08 <.0001 <.0001 
D2 MIP Plasmid 1.0413 0.1261 279.8 8.26 <.0001 <.0001 
D2 No F1 Plasmid 0.2864 0.1277 292.2 2.24 0.0256 0.1142 
D3 MC MIP -1.3379 0.1328 335 -10.08 <.0001 <.0001 
D3 MC No F1 -0.8160 0.1355 353 -6.02 <.0001 <.0001 
D3 MC Plasmid -0.7892 0.1362 353 -5.79 <.0001 <.0001 
D3 MIP No F1 0.5220 0.1286 299.5 4.06 <.0001 0.0004 
D3 MIP Plasmid 0.5488 0.1294 306.3 4.24 <.0001 0.0002 
D3 No F1 Plasmid 0.02683 0.1323 329 0.20 0.8394 0.9970 
D4 MC MIP -0.8133 0.1273 290.7 -6.39 <.0001 <.0001 
D4 MC No F1 -0.3797 0.1298 310.1 -2.92 0.0037 0.0193 
D4 MC Plasmid -0.5073 0.1296 309.4 -3.91 0.0001 0.0006 
D4 MIP No F1 0.4336 0.1269 284.9 3.42 0.0007 0.0040 
D4 MIP Plasmid 0.3060 0.1267 284.4 2.42 0.0164 0.0765 
D4 No F1 Plasmid -0.1276 0.1292 303.2 -0.99 0.3240 0.7565 
EGFP positive cell counts for each vector were analyzed as a negative binomial with total cell count 
as an offset term.  Vector effects within each donor were compared using least square means with 
use of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between 
the estimated responses for each vector; SE, standard error; DF, degrees of freedom; t value, t-test 
statistic; Pr > |t|, p-value associated with the t statistic; Adj P, adjusted p-value.  Significance was 
accepted at p<0.05.  Red highlighted adjusted p-values indicate no significant difference at α=0.05 
 
Table S10: Pairwise Comparisons Between Cationic Carriers for Each Promoter 
Promoter Cationic Carrier _Cationic Carrier Estimate SE DF t Value Pr > |t| Adj P 
CMV Lipofectamine 3000 Turbofect -0.2017 0.07151 9.14 -2.82 0.0197 0.0197 
EF1a Lipofectamine 3000 Turbofect 0.6563 0.07772 12.74 8.45 <0.0001 <0.0001 
EGFP positive cell counts for each cationic carrier were analyzed as a negative binomial with total cell count as an 
offset term.  Cationic carrier effects within each promoter were compared using least square means with use of Tukey-
Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the estimated responses for each 
cationic carrier; SE, standard error; DF, degrees of freedom; t value, t-test statistic; Pr > |t|, p-value associated with 
the t statistic.  Significance was accepted at p<0.05.   
 
  
Table S11: Pairwise Comparisons Between Cationic Carriers for Each Vector 
Vector Cationic Carrier _Cationic Carrier Estimate SE DF t Value Pr > |t| Adj P 
Plasmid Lipofectamine 3000 Turbofect -0.08462 0.09949 32.95 -0.85 0.4012 0.4012 
No F1 Lipofectamine 3000 Turbofect 0.5532 0.09832 31.46 5.63 <0.0001 <0.0001 
MC Lipofectamine 3000 Turbofect 0.1764 0.1038 38.9 1.7 0.0971 0.0971 
MIP Lipofectamine 3000 Turbofect 0.2643 0.09460 26.99 2.79 0.0095 0.0095 
EGFP positive cell counts for each cationic carrier were analyzed as a negative binomial with total cell count as an 
offset term.  Cationic carrier effects within each vector were compared using least square means with use of Tukey-
Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the estimated responses for each 
cationic carrier; SE, standard error; DF, degrees of freedom; t value, t-test statistic; Pr > |t|, p-value associated with 
the t statistic.  Significance was accepted at p<0.05.  Red highlighted p-values indicate no significant difference at 
α=0.05. 
 
Table S12: Pairwise Comparisons Between Cationic Carriers for Each Donor 
Donor Cationic Carrier _Cationic Carrier Estimate SE DF t Value Pr > |t| 
D1 Lipofectamine Turbofect 0.5510 0.1174 4.157 4.69 0.0085 
D2 Lipofectamine Turbofect 0.6193 0.1163 4.006 5.33 0.0060 
D3 Lipofectamine Turbofect -0.2048 0.1177 4.214 -1.74 0.1534 
D4 Lipofectamine Turbofect -0.05621 0.1155 3.906 -0.49 0.6526 
EGFP positive cell counts for each cationic carrier were analyzed as a negative binomial with total cell 
count as an offset term.  Cationic carrier effects within each donor were compared using least square means 
with use of Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the 
estimated responses for each cationic carrier; SE, standard error; DF, degrees of freedom; t value, t-test 
statistic; Pr > |t|, p-value associated with the t statistic.  Significance was accepted at p<0.05.  Red 






Table S13: Pairwise Comparisons Between Donors for Each Promoter 
Promoter Donor _Donor Estimate SE DF t Value Pr > |t| Adj P 
CMV D1 D2 -0.6892 0.2325 4.565 -2.96 0.0351 0.1143 
CMV D1 D3 -1.2501 0.2325 4.566 -5.38 0.0039 0.0141 
CMV D2 D3 -0.5609 0.2322 4.546 -2.42 0.0655 0.2012 
CMV D4 D1 1.5946 0.2323 4.553 6.86 0.0014 0.0053 
CMV D4 D2 0.9054 0.2321 4.533 3.9 0.0138 0.0474 
CMV D4 D3 0.3445 0.2321 4.534 1.48 0.2037 0.5133 
EF1a D1 D2 -0.3532 0.236 4.852 -1.5 0.1966 0.5041 
EF1a D1 D3 -0.4423 0.2369 4.923 -1.87 0.1218 0.3474 
EF1a D2 D3 -0.0891 0.2366 4.9 -0.38 0.7223 0.9798 
EF1a D4 D1 0.7838 0.2358 4.832 3.32 0.022 0.0752 
EF1a D4 D2 0.4306 0.2355 4.81 1.83 0.1293 0.3634 
EF1a D4 D3 0.3415 0.2364 4.879 1.44 0.2095 0.5285 
EGFP positive cell counts for each donor were analyzed as a negative binomial with total cell count as 
an offset term.  Donor effects within each promoter were compared using least square means with use of 
Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the estimated 
responses for each donor; SE, standard error; DF, degrees of freedom; t value, t-test statistic; Pr > |t|, p-
value associated with the t statistic; Adj P, adjusted p-value.  Significance was accepted at p<0.05.  Red 
highlighted adjusted p-values indicate no significant difference at α=0.05 
 
  
Table S14: Pairwise Comparisons Between Donors for Each Vector 
Vector Donor _Donor Estimate SE DF t Value Pr > |t| Adj P 
Plasmid D1 D2 -0.8555 0.2521 6.311 -3.39 0.0135 0.0509 
Plasmid D1 D3 -1.2511 0.2531 6.404 -4.94 0.0022 0.0088 
Plasmid D2 D3 -0.3956 0.252 6.3 -1.57 0.1652 0.4558 
Plasmid D4 D1 1.6229 0.252 6.298 6.44 0.0005 0.0023 
Plasmid D4 D2 0.7674 0.251 6.194 3.06 0.0214 0.0779 
Plasmid D4 D3 0.3718 0.2519 6.287 1.48 0.1882 0.5018 
No F1 D1 D2 -0.9938 0.2504 6.14 -3.97 0.007 0.0272 
No F1 D1 D3 -1.1298 0.2519 6.284 -4.49 0.0037 0.0148 
No F1 D2 D3 -0.136 0.2507 6.17 -0.54 0.6065 0.9454 
No F1 D4 D1 1.3472 0.2513 6.227 5.36 0.0015 0.0062 
No F1 D4 D2 0.3534 0.2501 6.113 1.41 0.2066 0.5351 
No F1 D4 D3 0.2174 0.2516 6.256 0.86 0.4195 0.8230 
MC D1 D2 0.1616 0.257 6.807 0.63 0.55 0.9195 
MC D1 D3 -0.7039 0.2565 6.754 -2.74 0.0298 0.1074 
MC D2 D3 -0.8655 0.2568 6.786 -3.37 0.0125 0.048 
MC D4 D1 1.3576 0.2541 6.506 5.34 0.0014 0.0056 
MC D4 D2 1.5192 0.2545 6.545 5.97 0.0007 0.003 
MC D4 D3 0.6537 0.2539 6.491 2.57 0.0393 0.1370 
MIP D1 D2 -0.397 0.2477 5.876 -1.6 0.1611 0.4438 
MIP D1 D3 -0.3001 0.2484 5.946 -1.21 0.2729 0.6446 
MIP D2 D3 0.09696 0.2484 5.941 0.39 0.7099 0.9780 
MIP D4 D1 0.4291 0.2481 5.915 1.73 0.1351 0.3875 
MIP D4 D2 0.03209 0.248 5.91 0.13 0.9013 0.9991 
MIP D4 D3 0.1291 0.2488 5.98 0.52 0.6226 0.9515 
EGFP positive cell counts for each donor were analyzed as a negative binomial with total cell count as 
an offset term.  Donor effects within each vector were compared using least square means with use of 
Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the estimated 
responses for each donor; SE, standard error; DF, degrees of freedom; t value, t-test statistic; Pr > |t|, p-
value associated with the t statistic; Adj P, adjusted p-value.  Significance was accepted at p<0.05.  Red 
highlighted adjusted p-values indicate no significant difference at α=0.05 
  
Table S15: Pairwise Comparisons Between Donors for Each Cationic Carrier 
Cationic Carrier Donor _Donor Estimate SE DF t Value Pr > |t| Adj P 
Turbofect D1 D2 -0.4871 0.2402 5.11 -2.03 0.0972 0.2897 
Turbofect D1 D3 -1.2241 0.2404 5.127 -5.09 0.0035 0.0132 
Turbofect D2 D3 -0.737 0.2402 5.113 -3.07 0.0271 0.0925 
Turbofect D4 D1 1.4928 0.2398 5.078 6.22 0.0015 0.0056 
Turbofect D4 D2 1.0057 0.2397 5.064 4.2 0.0083 0.0301 
Turbofect D4 D3 0.2687 0.2399 5.081 1.12 0.3127 0.6941 
Lipofectamine 3000 D1 D2 -0.5553 0.239 5.003 -2.32 0.0677 0.2113 
Lipofectamine 3000 D1 D3 -0.4683 0.2395 5.05 -1.96 0.1074 0.3142 
Lipofectamine 3000 D2 D3 0.08698 0.2391 5.02 0.36 0.7309 0.9817 
Lipofectamine 3000 D4 D1 0.8856 0.2389 5.003 3.71 0.0139 0.0492 
Lipofectamine 3000 D4 D2 0.3303 0.2386 4.973 1.38 0.2252 0.5576 
Lipofectamine 3000 D4 D3 0.4173 0.2391 5.019 1.74 0.1412 0.3926 
EGFP positive cell counts for each donor were analyzed as a negative binomial with total cell count as an 
offset term.  Donor effects within each cationic carrier were compared using least square means with use of 
Tukey-Kramer to adjust for multiple comparisons. Estimate, logarithm of the ratio between the estimated 
responses for each donor; SE, standard error; DF, degrees of freedom; t value, t-test statistic; Pr > |t|, p-value 
associated with the t statistic; Adj P, adjusted p-value.  Significance was accepted at p<0.05.  Red highlighted 
adjusted p-values indicate no significant difference at α=0.05 
 
Figure S1. Donor specific transfection efficiency fold changes for all pairwise comparisons of transfection 
conditions.  (A) Transfection efficiency fold changes for all pairwise comparisons of transfection 
conditions in D1 hAMSCs.  (B) Transfection efficiency fold changes for all pairwise comparisons of 
transfection conditions in D2 hAMSCs.  (C) Transfection efficiency fold changes for all pairwise 
comparisons of transfection conditions in D3 hBMSCs.  (D) Transfection efficiency fold changes for all 




Figure S2. Donor specific transgenic luciferase activity fold changes for all pairwise comparisons of 
transfection conditions.  (A) Transgenic luciferase activity fold changes for all pairwise comparisons of 
transfection conditions in D1 hAMSCs.  (B) Transgenic luciferase activity fold changes for all pairwise 
comparisons of transfection conditions in D2 hAMSCs.  (C) Transgenic luciferase activity fold changes 
for all pairwise comparisons of transfection conditions in D3 hBMSCs.  (D) Transgenic luciferase activity 
fold changes for all pairwise comparisons of transfection conditions in D4 hBMSCs.  Fold changes are 
presented relative to column conditions.
 
Figure S3. Relative transgenic mRNA transcripts at 12- and 24-hours following delivery of complexes as a 
function of DNA vector and promoter.  (A) Transgenic mRNA transcripts, relative to the plasmid vector 
with the CMV promoter, for D1 hMSCs 12 hours after delivery of DNA vectors complexed with Turbofect.  
(B) Transgenic mRNA transcripts, relative to the plasmid vector with the EF1a promoter, for D1 hMSCs 
12 hours after delivery of DNA vectors complexed with Turbofect.  (C) Transgenic mRNA transcripts, 
relative to the plasmid vector with the CMV promoter, for D1 hMSCs 24 hours after delivery of DNA 
vectors complexed with Turbofect.  (D) Transgenic mRNA transcripts, relative to the plasmid vector with 
the EF1a promoter, for D1 hMSCs 24 hours after delivery of DNA vectors complexed with Turbofect.  Data 
in bar graphs are represented as mean ± SEM (n=6).  *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
  
Figure S4. Cationic carrier effects on total cell counts in different donors of hMSCs derived from adipose 
tissue and bone marrow.  Total cell counts for a DNA vector complexed with Turbofect were divided by 
total cell counts for the same DNA vector complexed with Lipofectamine 3000 for each donor to calculate 
total cell count ratios, which is an indirect measure of toxicity and/or proliferative effects of Turbofect 
relative to Lipofectamine 3000.  Data in bar graphs are represented as mean ± SEM (n=48/donor).  ****, 
p<0.0001 
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